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CombinationsThe discovery and increased understanding of the complex interactions regulating the immune system have
contributed to the pharmacologic activation of antitumor immunity. The activity of effector cells, such as T and
NK cells, is regulated by an array of activating and attenuating receptors and ligands. Agents that target these
molecules can modulate immune responses by exerting antagonistic or agonistic effects.
Several T- or NK-cell modulators have entered clinical trials, and two have been approved for use. Ipilimumab
(Yervoy®, Bristol-Myers Squibb) and nivolumab (OPDIVO, Ono Pharmaceutical Co., Ltd./Bristol-Myers Squibb)
were approved for the treatment of metastatic melanoma, in March 2011 in the United States, and in July
2014 in Japan, respectively.
The clinical activity of these two antibodies has not been limited to tumor types considered sensitive to immuno-
therapy, and promising activity has been reported in other solid and hematologic tumors.
Clinical development of ipilimumab and nivolumab has presented unique challenges in terms of safety and
efﬁcacy, requiring the establishment of new evaluation criteria for adverse events and antitumor effects. Guide-
lines intended tohelp oncologists properlymanage treatment in viewof these non-traditional features have been
implemented.
The introduction of this new modality of cancer treatment, which is meant to integrate with or replace the
current standards of care, requires additional efforts in terms of optimization of treatment administration,
identiﬁcation of biomarkers and application of new clinical trial designs. The availability of immune modulators
with different mechanisms of action offers the opportunity to establish immunological combinations as new
standards of care.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
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Engaging a patient's own immune system to prevent and/or combat
diseases has been adopted formany years for chronic and acute infections
(Hotchkiss &Moldawer, 2014). Analogous approaches for cancer therapy
have been explored for many years, but with only a small number of
successes in the last century leading to regulatory approval (interferon
alfa 2A and 2B for hairy cell leukemia in 1986, intravesical Bacillus
Calmette–Guérin (BCG) for recurrent, localized bladder cancer in
1989, and aldesleukin for renal cancer in 1992). Additional indications
were subsequently granted to interferon alfa 2A for chronic myeloid
leukemia, to interferon alfa 2B for follicular and AIDS-related non-
Hodgkin's lymphoma and for resected melanoma, and to aldesleukin
for metastatic melanoma (Drugs@FDA, 2014).
Within the last few years, a deeper understanding of the immune
system at the molecular level has spurred a renaissance of interest
and resulted in successful development for therapeutic vaccines
(sipuleucel-T in 2010 for prostate cancer) and immunostimulatory
monoclonal antibodies (ipilimumab in 2011, in the U.S., and nivolumab
in 2014, in Japan, for metastatic melanoma). While still at the experi-
mental level, additional immunologic therapeutic modalities involving
the two classes mentioned above, as well as innovative approaches
utilizing adaptive and innate immunity andmodiﬁed cellular therapies,
promise to further advance immuno-oncology as a mainstay in the
future treatment of malignancies. In this paper wewill report our direct
experience in the contributions that Bristol-Myers Squibb (BMS) has
made to this area of cancer research, limited to the immunomodulatory
compounds that have already reached the stage of clinical development.
2. Targeting the immune checkpoints
The immune response normally begins when foreign proteins and
antigens are recognized, captured and processed into peptides by
antigen-presenting cells (APCs), which then present such peptides in
the context of a major histocompatibility complex (MHC) to T cells.
Recognition of this complex occurs via a speciﬁc T-cell receptor. However,
activation of the T cell typically requires an additional signal such as theFig. 1. Immune checkpoint modulators. aThe antibody has shown evidence of an antagonistic ef
members of this familywhich are expressed on T cells; the corresponding ligand (CD40L) is exp
antigen 4; GITR: Glucocorticoid-induced tumor necrosis factor receptor; LAG-3: Lymphocyte aco-stimulatory interaction between the CD80 (B7.1) and CD86 (B7.2)
ligands expressed by the APC and the CD28 receptor expressed by the
T cell. The activation of T cells is further regulated by the balance of
inhibitor (i.e. checkpoint) and co-stimulatory pathways, which are
critical in healthy subjects to prevent auto-immunity (producing self-
tolerance) and to protect normal tissues when the immune system is
activated against a pathogen (Pardoll, 2012).Many immune checkpoint
or co-stimulatory molecules regulating the interaction between ligands
on the APC and receptors on the T cell have been identiﬁed (Fig. 1). The
targeting of cell membrane receptors is possible withmolecules such as
monoclonal antibodieswhich canmimic or block the effect of a receptor
or of a ligand and thereby enhance the immune response (Melero et al.,
2013b).
2.1. Cytotoxic T-lymphocyte antigen 4 (CTLA-4)
The CTLA-4 gene was originally discovered by a French group using
subtractive hybridization to identify genes enriched in cytotoxic T cells.
This group showed that the gene was not constitutively expressed, but
induced in activated T cells. However, initially its function was not
fully understood (Brunet et al., 1987). A group of scientists at BMS
ﬁrst discovered that the B7 antigens, present on B-lymphocytes, are a li-
gand for the CD28 receptor on the T-lymphocytes (Linsley et al., 1991a).
Shortly thereafter, they were able to identify CTLA-4 (also known as
CD152) as a higher-afﬁnity receptor for B7 than CD28 (Linsley et al.,
1991b). This seminal work stimulated further research in the area of
immunosuppression, which eventually led to the successful develop-
ment of soluble CTLA-4 molecules such as abatacept (Orencia®, BMS),
approved in 2005 for the treatment of rheumatoid arthritis and
belatacept (Nulojix®, BMS), approved in 2011 for prophylaxis of kidney
transplant rejection (Drugs@FDA, 2014). Investigators at the University
of Chicago and the Dana-Farber Cancer Institute discovered that CTLA-4
can function as a negative regulator (Green et al., 1994; Walunas et al.,
1994). Two groups generated CTLA-4 knock-out mice, demonstrating
massive lymphoproliferation and leading to death, thereby conﬁrming
the regulatory (negative) effect of CTLA-4 on T cells (Tivol et al., 1995;
Waterhouse et al., 1995).fect. bCD40 is a member of the TNF receptor family, expressed on APCs in contrast to other
ressed on the T cell. APC: antigen-presenting cell; CTLA-4: CTLA-4: Cytotoxic T-lymphocyte
ctivation gene-3; PD-1: Programmed death-1; PD-L1: Programmed death ligand 1.
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University of California, Berkeley and then at Memorial Sloan-Kettering
in New York that clariﬁed that the outcome of T-cell activation was
determined by the balance of CD28 (stimulatory signal) and CTLA-4
(inhibitory signal) (Krummel & Allison, 1995). Allison's group went on
to demonstrate that in vivo blockade of the CTLA-4 receptor resulted in
an antitumor effect in a murine model and that this effect was mediated
by T-lymphocyte proliferation, thus identifying this as a potential novel
mechanism for anticancer therapy (Chambers et al., 2001).
In collaboration with Allison's group, scientists at Medarex (now
BMS's Biologics Discovery, California) eventually demonstrated that
CTLA-4 blockade produces both a direct enhancement of T-cell effector
function and a concomitant inhibition of regulatory T-cell activity
(Peggs et al., 2009).
Shortly after the initial discovery by Allison, Alan Korman and Nils
Lonberg at Medarex decided to develop a fully human anti-CTLA-4
antibody for anticancer therapy. The antibody they selected, now called
ipilimumab, is a human IgG1 Kappa immunoglobulin with high binding
afﬁnity to the CTLA-4 receptor and that blocked its interaction with
B7.1 and B7.2 (Keler et al., 2003). After ipilimumab had initiated clin-
ical trials, another monoclonal antibody directed against CTLA-4,
tremelimumab (Astra-Zeneca/MedImmune, originally known as
ticilimumab, CP-675,206 when under the sponsorship of Pﬁzer ﬁrst,
and Debiopharm second) (Ribas et al., 2005) was also selected for
clinical development. In contrast to ipilimumab, tremelimumab is an
IgG2 isotype antibody. Human IgG2 isotype antibodies do not typically
engage cell-mediated effector function as efﬁciently as human IgG1
isotype antibodies, and it is possible that this isotype difference could
impact the relative activity of these two agents. Effector-mediated de-
pletion of intratumoral regulatory T cells is an important component
of the activity of anti-CTLA-4 antibodies in mouse tumor models (M.J.
Selby et al., 2013; Simpson et al., 2013); however, there have been no
side-by-side comparisons of the clinical activity of ipilimumab and
tremelimumab, and both antibodies have shown antitumor activity
and similar inﬂammatory adverse events in melanoma patients.
2.2. Programmed death 1 (PD-1)
TasukuHonjo and colleagues at Kyoto University discovered the gene
encoding the PD-1 receptor (Ishida et al., 1992). PD-1 (also known as
CD279) is a transmembrane protein receptor which is not detectable
on resting T cells but is highly expressed by activated T cells (Pardoll,
2012).
Two ligands have been identiﬁed for PD-1 (Freeman et al., 2000;
Latchman et al., 2001): PD-L1 (originally referred to as B7 Homolog 1
or B7-H1) by Lieping Chen's group at the Mayo Clinic (Dong et al.,
1999) and PD-L2 (originally referred to as B7-Dendritic Cell or B7-DC)
by Drew Pardoll's group at Johns Hopkins (Tseng et al., 2001). In 2002,
Chen's group found that that many human tumors overexpress PD-L1,
and that mouse PD-L1 expression on tumor cells confers a growth
advantage in immune competent syngeneic mouse tumor models
(Dong et al., 2002). That same year, Honjo and colleagues reported
that a monoclonal antibody to mouse PD-L1 had therapeutic activity
in syngeneic mouse tumor models and that PD-1-deﬁcient mice are
more resistant to transplanted tumors that wild-type mice (Iwai et al.,
2002). Medarex scientists, led by Alan Korman, developed human
antibodies against human PD-1 as well as, separately, against its ligand
PD-L1, and demonstrated their ability to enhance T-cell responses
in vitro. Antitumor effects in themicewere also observedwith surrogate
antibodies to mouse PD-1 and PD-L1 (Wang et al., 2014). Nivolumab
(MDX-1106, BMS-936558), a fully human, monoclonal immunoglobulin
IgG4 antibody that binds to the PD-1 receptor, was selected for clinical
development. Of note, nivolumab is able to block the interaction of
PD-1 with both of its ligands, PD-L1 and PD-L2.
A number of additional monoclonal antibodies reported to target
the PD-1 receptor are currently under development. These includepembrolizumab (MK-3475, formerly known as lambrolizumab, Merck),
a humanized IgG4 (Hamid et al., 2013), pidilizumab (CT-011, formerly
known as CT-AcTibody or BAT, CureTech and, temporarily, Teva), a
humanized IgG1 (Berger et al., 2008), and AMP-514 (MEDI0680,
Amplimmune and MedImmune/Astra-Zeneca) which recently entered
the clinic (ClinicalTrials.gov; NCT02013804). In the case of pidilizumab,
its speciﬁcity for PD-1 binding has been questioned (Pardoll, 2012).
Another approach to target the PD-1 receptor, which has reached
the clinic, is the recombinant protein composed of the extracellular do-
main of PD-L2 (B7-DC) fused to the Fc portion of IgG1, called AMP-224
(Amplimmune and Glaxo Smith-Kline) (Smothers et al., 2013).
2.3. Lymphocyte activation gene 3 (LAG-3)
LAG-3 (also known as CD223) was discovered in 1990 as a gene that
was expressed in activated, but not resting, T andNK cells (Triebel et al.,
1990). LAG-3 functions as an inhibitory receptor on T cells, and by
increasing the effect of regulatory T cells (Huard et al., 1995; Grosso
et al., 2007). In mouse models of chronic viral disease, LAG-3 is one of
the key inhibitory receptors, along with PD-1, that contribute to T-cell
‘exhaustion’ (Wherry, 2011). The ligand for LAG-3 is a MHC class II
molecule.
Simultaneous blockade of LAG-3 and PD-1 synergistically enhance
T-cell activity and antitumor immunity in mouse models (Woo et al.,
2012). Alan Korman's group at Medarex (now part of BMS) produced
amonoclonal antibody directed against LAG-3 that has recently entered
clinical trials: BMS-986016 (BMS) alone or in combination with
nivolumab (ClinicalTrials.gov; NCT01968109).
2.4. T-cell agonists
Pharmacologic blockade of checkpoints inhibitors which ‘remove
the brake’ imposed on the immune system, have been clinically validated.
More recently, there has been also an intense research aimed at devel-
oping potential agonist compounds that would ‘press on the gas pedal’
to directly activate T cells. These agonists function only in concert with
T-cell receptor signaling. Several of these compounds have reached the
stage of clinical development.
2.4.1. CD137
CD137 (also known as 4-1BB or TNFRSF9) was identiﬁed in the early
90's (Pollok et al., 1993) and has one ligand, CD137-L (or 4-1BBL),which
is present on APCs. Monoclonal antibodies that directly activate CD137
can co-stimulate and enhance the effect of T cells, increasing their cyto-
toxicity and protecting them from programmed death, as initially re-
ported by investigators at the BMS Pharmaceutical Research Institute
in Seattle (Melero et al., 1998). An additional interesting property of
this agonistic antibody is the ability to enhance NK-cell function in
antibody-dependent cell-modulated cytotoxicity (ADCC), thus enhanc-
ing the antitumor effects of antibodies which target tumor cells directly,
such as rituximab, cetuximab and trastuzumab (Kohrt et al., 2012).
The BMS group developed a number of monoclonal antibodies
directed against CD137 (Melero et al., 1997), from which urelumab
(BMS-663513), a fully human IgG4, was selected for clinical develop-
ment (Sznol et al., 2008). Anothermonoclonal antibody directed against
CD137, an IgG2 humanizedmolecule (PF-05082566, Pﬁzer) has recently
entered the clinic (Segal et al., 2014).
2.4.2. Other members of the tumor necrosis factor superfamily
The tumor necrosis factor (TNF) receptor family (or ‘superfamily’)
contains a number of receptors which are expressed on cells of the im-
mune system, as well as their trans-membrane ligands (Armitage,
1994). One such receptor is CD27 (also known as TNFRSF7), which is
found on NK cells, as well as on T- and B-cell populations (Hendriks
et al., 2000). The ligand for CD27 is CD70, which has been found on
activated dendritic cells including thymic dendritic cells in humans.
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ferentiation of CD8+ T-cells into effector cytotoxic T cells (Brown
et al., 1995). An anti-CD27 human antibody, varilumab (CDX-1127,
Celldex Therapeutics) has entered clinical trials, both in hematologic
malignancies (Ansell et al., 2014) and in solid tumors (Infante et al.,
2014). Combinations of varilumab with BMS's anti-PD-1 monoclonal
nivolumab, andwith Oncothyreon's tumor-associated antigenMUC1
vaccine, ONT-10, are planned for clinical development.
Another co-stimulatory molecule is OX40 (also known as CD134 or
TNFRSF4), and a murine anti-human OX40 monoclonal antibody has
been tested in the clinic (Weinberg et al., 2006; Melero et al., 2013a).
OX40 is currently the target of a second antibody in development,
MEDI6383 (MedImmune) (ClinicalTrials.gov; NCT02221960).
The glucocorticoid-induced TNF receptor (GITR) has been targeted
by an agonistic humanized anti-GITR IgG1 antibody (TRX518, Tolerx
and GITR Inc.) (Rosenzweig et al., 2010) and by another agonistic
antibody, MK-4166 (Merck) (ClinicalTrials.gov; NCT02132754).
Finally, a member of the TNF superfamily is CD40, which is expressed
on APCs, whereas its ligand (CD40L) is expressed on the T cell (Melero
et al., 2013a). Many therapeutic antibodies are directed to CD40:
CP-870,893 (Pﬁzer and VLST) (Vonderheide et al., 2007), dacetuzumab
(Seattle Genetics) (Khubchandani et al., 2009), Chi Lob 7/4 (Southampton
University) (Johnson et al., 2010), and lucatumumab (Novartis)
(Bensinger et al., 2012). Of note, these antibodies can actually present
very different characteristics, including either antagonism or agonism,
and agonist activity may be dependent on, or potentiated by, Fc recep-
tor ligation (Li & Ravetch, 2013). In addition, the potential for depletion
of regulatory T-cells using Fc regions that bind to activating receptors
may provide an additional mechanism of action of these antibodies, as
has also been observed for antibodies to GITR and CTLA-4 (Bulliard
et al., 2013; M.J. Selby et al., 2013; Simpson et al., 2013).
2.5. Ligands
2.5.1. PD-L1
The programmed death ligand 1 (PD-L1 or B7-H1 or CD274) is
a member of the B7 ligand family and is more broadly expressed
than PD-L2 (Pardoll, 2012). PD-L1 is not only induced on activated
T-lymphocytes, but also on other activated non-T-lymphocyte cells, in-
cluding B and NK cells, as well as on many tumors. Moreover, when a
prolonged presence of an antigen occurs, as in chronic viral infections,
a persistent high expression of PD-1 is induced that can produce
exhaustion or anergy of the immune system. Inﬂammatory conditions
at the tissue and/or tumor level induce PD-L1 (and PD-L2) expression.
Finally, PD-L1 can interact with the CD80 receptor on T cells, sending
a further immunosuppressive signal. Targeting this major inhibitory
ligand can thus produce complex and powerful effects.
The ﬁrst monoclonal antibody directed against the PD-L1 ligand to
enter clinical trials was BMS-936559, developed by BMS concomitantly
with the anti-PD-1 monoclonal antibody nivolumab. BMS-936559 is
a high afﬁnity, fully human, immunoglobulin IgG4 that can block
the binding of PD-L1 to both PD-1 and CD80 (B7.1) (Brahmer et al.,
2012).
A number of additional PD-L1 targeted antibodies have rapidly
followed into the clinic, including MPDL3280A (Roche/Genentech), a
human monoclonal IgG1 antibody containing an engineered Fc-domain
to eliminate Fc receptor binding (Gordon et al., 2013); MEDI4736
(AstraZeneca/MedImmune), a human immunoglobulin G1 kappa, also
engineered to eliminate Fc-receptor binding (Lutzky et al., 2014), and
MSB0010718C (EMD Serono), a human IgG1 antibody (Heery et al.,
2014).
2.5.2. CD70
CD70 is a transmembrane cell surface protein that is highly expressed
in clear-cell renal carcinoma as well as in B-cell non-Hodgkin's lympho-
ma. CD70 is the ligand for CD27, as described before.BMSdeveloped antibodies directed toCD70with the intent of utilizing
them for immuno-conjugate targeting. A Phase I trial of one such com-
pound, BMS-936561 (MDX-1203), was recently reported (Owonikoko
et al., 2014). A second CD70-directed monoclonal, ARGX-110 (arGEN-X)
has also subsequently entered the clinic (Awada et al., 2014).
2.5.3. B7-H3
A new member of the B7 family, B7-H3 has been recently described
(Loos et al., 2010). The potential co-inhibitory T-cell receptor for this li-
gandhas not been identiﬁed. Ahumanized IgG1 including Fc engineering
and directed to this target has been developed and brought to the clinic,
MGA271 (MacroGenics and Servier) (ClinicalTrials.gov; NCT01391143).
3. Clinical development
Given the nature and the extent of this review, we will cover in this
section only the compounds that have reached the stage of clinical
development under BMS sponsorship. Other compounds that have
reached this stage have been mentioned in the previous section.
3.1. Ipilimumab (anti-CTLA-4)
The development of ipilimumab has been previously reviewed in
detail (Hoos et al., 2010a; Wolchok et al., 2013a). For the purpose of
this paper, we would like to focus on the critical choices and ﬁndings
that occurred during its development and update the overall results.
In laboratory models, antibody blockade of CTLA-4 induced antitu-
mor immunity mediated by CD4+ and CD8+ effector T cells. Of note,
early preclinical testings were conducted which involved combinations
with cytokines, vaccines and chemotherapy, posing the basis for the
ensuing clinical development of novel regimens. To translate these
preclinical results to the clinical setting, scientists at Medarex (now
part of BMS) used transgenic mice comprising human immunoglobulin
genes to generate fully humanmonoclonal antibodies to humanCTLA-4.
Ipilimumab, the antibody selected for clinical development, was initially
designated as 10D1 orMDX-010 (Grosso& Jure-Kunkel, 2013). To accel-
erate entry into clinical testing, the material used in the initial Phase I
trials was derived from the original transgenic mouse hybridoma;
however all subsequent and ongoing clinical trials (and the approved
version of the drug) were conducted with material derived from a
transfectoma (Weber et al., 2008).
3.1.1. Phase I
The clinical development of ipilimumab began in mid-2000 with
monotherapy Phase I trials conducted under the sponsorship ofMedarex
(Tchekemedyian et al., 2002;Hodi et al., 2003), aswell aswith the collab-
oration of the Surgery Branch of the U.S. National Cancer Institute (NCI),
which focused on combinations with a peptide vaccine, gp100 (Phan
et al., 2003), andwith aldesleukin (Maker et al., 2005). TheNCI investiga-
tors also conducted a monotherapy intra-patient dose-escalation trial
(Maker et al., 2006).
In the initial experience, ipilimumab presented a characteristic set of
mechanismof action-related (‘on-target’) side effects (see safety section
later), but without reaching a dose-relatedmaximum tolerated level up
to 20 mg/kg. In addition, although the rate of objective responses was
not particularly high, some impressively durable antitumor effects,
including complete (CR) and partial (PR) responses, were observed.
Remarkably, objective responses were seen in each of the Phase I trials
completed.
The Phase I studies accrued mostly patients with heavily pretreated,
metastatic malignant melanoma. Because of the early efﬁcacy observa-
tions in this disease, a small trial of ipilimumab in combination with
another vaccine (a combination of tyrosinase, gp100 and MART-1
peptides) was conducted in the adjuvant setting (Sanderson et al.,
2005), a relatively novel approach to clinical development at such an
early junction.
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Three Phase II trials were initiated in patients with melanoma. The
ﬁrst trial employed the combination of ipilimumab with gp100 (Attia
et al., 2005) in a population of 56 mostly pretreated patients with
metastatic disease, and achieving two CR and ﬁve PR (13% response
rate), most of them of long duration.
The second trial randomized 72 chemotherapy-naïve patients
with metastatic disease to receive either ipilimumab monotherapy or
ipilimumab in combination with dacarbazine (DTIC) (Hersh et al.,
2011), achieving two PR (5%) and two CR and three PR (14%), respec-
tively, also of long duration, suggesting that a cytotoxic chemotherapy
did not inhibit ipilimumab activity.
The third trial treated 75 patients in the adjuvant setting with
ipilimumab and the peptide vaccine utilized in the adjuvant Phase I
trial for a prolonged period of time (one year) (Sarnaik et al., 2011). In
this small trial, neither median relapse-free (RFS) nor overall survival
(OS) was reached after a median follow-up of 29.5 months.
These Phase II trials conﬁrmed the clinical behavior of ipilimumab,
both in terms of safety and efﬁcacy, as observed in the early Phase I
experience. They all utilized an ipilimumab dosage of 3 mg/kg which,
although not the maximum tolerated dose, induced both antitumor ef-
fects andmanageable toxicities.With the exception of the adjuvant trial,
these early trials administered only a limited number of four ‘induction’
doses of ipilimumab every 3 weeks.
In 2005, Medarex initiated a collaboration with BMS to facilitate
the development of ipilimumab as well as of the gp100 vaccine
(MDX-1379). This collaboration was anchored by the expertise that
both companies had developed on immunology in general, and on the
CTLA-4 target in particular. Less than ﬁve years later, in 2009, BMS
acquired Medarex and its entire pipeline of experimental products
and immune modulators.
At the beginning of the collaboration a number of additional Phase II
trials in metastatic melanoma were launched. The goal of these trials
was to expand the experience with ipilimumab, to further investigate
dosing (dose–effect relationship) and duration (reinduction and main-
tenance) of treatment and to better understand the mechanism of
action. These trials suggested the existence of a potential dose–effect
for ipilimumab over the range of 0.3, 3 and 10 mg/kg for both efﬁcacy
and safety (Wolchok et al., 2010a), explored potential biomarkers in
the tumor microenvironment (Hamid et al., 2011), tested whether theTable 1
Single-agent and combination activity of ipilimumab in patients with metastatic melanoma (P
Author (year) Regimen (mg/kg) Prior Rx N
Weber et al. (2008) 2.8–20 79%
72% immuno Rx
52% chemo Rx
8
Phan et al. (2003) 3 + gp100 86% 1
Attia et al. (2005)a 3 + gp100 76%
73% immuno Rx
38% chemo Rx
5
Hersh et al. (2011) 3
3 + DTIC
57% (51% immuno Rx)
48% (40% immuno Rx)
3
3
Maker et al. (2005)a 0.1–3 + aldesleukin 66%
64% immuno Rx
22% chemo Rx
3
Maker et al. (2006)a 3 or 5 up to 9 94%
85% immuno Rx
55% chemo Rx
8
Wolchok et al., 2010a 0.3
3
10
100%
all
arms
7
7
7
Hamid et al., 2011 3
10
73%
77%
4
4
Thompson et al. (2012) 10
10 + budesonide
56%
36%
5
5
O'Day et al. (2010) 10 100% 1
CR: Complete response; DTIC: Dacarbazine; N/A: Not available; NR: Not reached; PR: partial re
a Results updated in Prieto et al. (2012).local prophylaxis with budesonide could improve the safety proﬁle
(Thompson et al., 2012), and conﬁrmed on a large database the effec-
tiveness of the compound (O'Day et al., 2010) when utilized as a single
agent in patients with advanced disease. Of note, consistent efﬁcacy in
patients with advanced melanoma was observed in the entire Phase II
experience with ipilimumab, whether the drug was administered alone
or in combination, whether at lower (3 mg/kg) or higher (10 mg/kg)
dosages, and whether in heavily pretreated or in previously untreated
patients (Table 1). Besides the consistency of the results, the observa-
tion of durable effects producing long-term survival in about 20 to
25% of the patients was particularly encouraging. Long-term survival
updates from these and other trials have been reported (Hersh et al.,
2011; Prieto et al., 2012; Lebbé et al., 2014).3.1.3. Phase III in melanoma
The large experience accumulated with ipilimumab in melanoma
prompted the launch of three Phase III trials. The ﬁrst of these trials
compared, in previously treated patients, the peptide vaccine gp100
alone, ipilimumab alone (at 3 mg/kg) and their combination and was
based on the Phase 2 studies of this regimen. Indeed, the 1:1:3 random-
izationwas originally aimed at identifying the individual contribution of
the two components of the combination. Only four induction doses
were administered, but reinduction with the same treatment assigned
at randomization was allowed upon relapse. This trial, for the ﬁrst
time in the history of the treatment of metastatic melanoma and for a
T-cell checkpoint inhibitor, demonstrated a signiﬁcant improvement
in overall survival (OS) for both of the ipilimumab-containing arms as
compared with the vaccine alone (Hodi et al., 2010). A reduction of
the risk of death of about one-third in the two ipilimumab arms resulted
in the ﬁrst regulatory approval of ipilimumab.
Secondary endpoints such as objective response rates, according to
World Health Organization (WHO) criteria (1.5 vs. 10.9 vs. 5.7%), and
progression-free survival (PFS) (with medians of 2.76 vs. 2.86 vs. 2.76
months, respectively, for gp100 alone vs. ipilimumab alone vs. the com-
bination but with a signiﬁcant reduction of the risk of progression, as
compared to the vaccine alone, of 36% with ipilimumab alone and 19%
for the combination), favored both ipilimumab-containing arms over
the vaccine alone. The combination regimen, however, was no better
than ipilimumab alone.hase I and II trials).
o. pts. CR + PR CR + PR + SD Durability (median, months)
7 4 (5%) 18 (21%) Responses: all N 6 months
4 3 (21%) 5 (36%) Responses: 11+ to 15+ months
6 7 (13%) N/A Responses: 4 to 99+ months
OS: 14
7
5
2 (5%)
5 (14%)
8 (22%)
13 (37%)
OS: 11.4
OS: 14.3
6 8 (22%) N/A Responses: 5 to 89+ months
OS: 16
5 17 (20%) N/A Responses: 5 to 76+ months
OS: 13
3
2
2
–
3 (4%)
8 (11%)
10 (14%)
19 (26%)
21 (29%)
OS: 8.6
OS: 8.6
OS: 14.6
0
2
3 (8%)
5 (12%)
16 (40%)
8 (19%)
OS: 12.9 PFS: 2.6
OS: 11.8 PFS: 2.6
7
8
9 (16%)
7 (12%)
20 (35%)
18 (31%)
OS: 19.3 (30.5 UT, 14.8 PT)
OS: 17.4 (NR UT, 8.5 PT)
55 9 (6%) OS: 10.2
sponse; PT: Pretreated; Pts: Patients; Rx: Therapy; SD: Stable diseases; UT: Untreated.
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untreated patients with metastatic disease (Robert et al., 2011). In this
trial DTIC, the only universally accepted standard of care for the treat-
ment of advancedmelanoma until 2011, was compared to the combina-
tion of DTIC and ipilimumab at 10 mg/kg in a double-blinded, placebo-
controlled study design. After the completion of the induction Phase,
maintenance with blinded ipilimumab 10 mg/kg or placebo was admin-
istered every 12 weeks. Again, the primary endpoint of superiority in OS
wasmet by the experimental arm,with a reduction of the risk of death of
28%.Whereas objective response rates (10.3% vs. 15.2% byWHO criteria,
p = 0.09) did not differ signiﬁcantly, PFS was signiﬁcantly prolonged by
24% in the ipilimumab combination arm (p=0.0006), despite the lack of
numerical difference between themedians. Also for this trial a long-term
survival update has been reported (Maio et al., 2013).
The third Phase III trial was conducted in the post-surgical setting in
patientswith high-risk stage IIIA–C disease (Eggermont et al., 2014) and
compared ipilimumab at 10 mg/kg with a placebo. As in the other
preceding Phase II and III trials of ipilimumab in metastatic melanoma,
an induction regimen of four doses administered every three weeks
was adopted. However, this particular study also provided for the ad-
ministration of maintenance therapy (or placebo) every 12 weeks for
a maximum of three years. This study as well met its primary endpoint
of RFS, as assessed by an Independent Review Committee, showing a
signiﬁcant reduction of the risk of recurrence by 25% (median 26.1 vs.
17.1 months for ipilimumab vs. placebo, p = 0.0013). Although the
follow-up for the secondary endpoint of OS was not sufﬁciently mature
at the time of reporting, a characteristic ‘leveling’ of the RFS curve,Fig. 2. Phase III trials of ipilimumab in melanoma. CI: Conﬁdence interval; DTIC: Dacarbazinereminiscent of what was observed with OS in all the other ipilimumab
trials, was reported.
Indeed, it is remarkable that all of the Phase III trials conducted with
ipilimumab in malignant melanoma have met their primary efﬁcacy
objective (Fig. 2).3.1.4. Other experiences with monotherapy in melanoma
When the effects of ipilimumab became evident in patients with ad-
vanced, heavily pretreated melanoma accrued to the Phase II program
and before the results of the Phase III trials became available, the ques-
tion of initiating an Expanded Access Program (EAP) arose. Indeed, such
a programwas started in early 2008,ﬁrst in theU.S. and then elsewhere,
utilizing the 10mg/kg dose. Only after the results of the Phase III trial in
pretreated patients became available, the program was amended to
adopt the 3 mg/kg dosage. Rules on data collection for such programs
vary from country to country but, when reportable, results from these
programs have been published from several nations such as Italy
(Altomonte et al., 2009; Queirolo et al., 2013), Spain (Berrocal et al.,
2013), the United Kingdom (Ahmad et al., 2013), Brazil (Schmerling
et al., 2014), France (Chasset et al., 2014), Canada (Lee-Ying et al.,
2014), and the U.S. (K.A. Margolin et al., 2013).
Not only have these initiatives allowed an early access to the drug,
but they have also conﬁrmed the clinical results on a very large scale
and contributed useful additional information on the performance of
the drug in patient subsets that might have not been accrued in sufﬁ-
cient numbers to the Phase II and III programs.; HR: Hazard ratio; Ipi: Ipilimumab; OS: Overall survival; RFS: Recurrence-free survival.
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spective subsets analyses, these data have contributed to the knowledge
of the effects of ipilimumab in patients with stabilized brain metastases
(Weber et al., 2011), active brain metastases (Margolin et al., 2012), in
previously untreated patients given the 3 mg/kg dose (K. Margolin
et al., 2013; Patt et al., 2013), in patients with and without HLA-A2
mutations (Wolchok et al., 2010b), with and without BRAF and NRAS
mutations (Shahabi et al., 2012; Queirolo et al., 2013) and in patients
with uveal (Danielli et al., 2012; Luke et al., 2013; Moser et al., 2014;
Piulats Rodriguez et al., 2014) and acral melanoma (Deo, 2014;
Johnson et al., 2014a; Zimmer et al., 2014).
Finally, a number of other analyses of ipilimumab effects according
to baseline characteristics such as age (Chiarion-Sileni et al., 2013),
baseline lactate dehydrogenase (LDH) levels (Smylie et al., 2009),
good and poor prognostic factors (Schadendorf et al., 2009) and out-
comes of prior targeted or immunological therapy (Joseph et al., 2011;
Ackerman et al., 2012) have also been reported.
Long-term follow-up was recently collected and analyzed from all
completed Phase II and Phase III trials in metastatic disease, as well as
from the ongoing follow-up of patients accrued to the EAP (Fig. 3). With
a large database comprising more than 4800 patients, and a follow-up
which currently extends up to 10 years from initiation of ipilimumab, it is
remarkable that the OS Kaplan–Meier curve appears to show a sustained
plateau after two to three years from the beginning of therapy, with
about one-ﬁfth of the patients presenting prolonged OS results.3.1.5. Other experiences with combinations in melanoma
The positive outcome of the Phase III trial of ipilimumab with DTIC
demonstrated that the combinationwas superior toDTIC alone. However,
due to its design, it did not address the issue of a potential detrimental
effect of chemotherapy to immunotherapy. A supportive randomized
trial was thus carried out in melanoma patients, and it did not document
any relevant pharmacokinetic interactions of ipilimumabwhen combined
with DTIC or with paclitaxel and carboplatin (J. Weber et al., 2013).
A small randomized trial in patients with melanoma testing the
concomitant administration of paclitaxel, carboplatin and ipilimumab
vs. its sequential administration (ipilimumab delayed by one week)
seemed to favor in response rate and disease control the sequential
administration (Jamal et al., 2014).
Additional trials have tested combinations of ipilimumab with
temozolomide, a drug with similarities to DTIC (Patel et al., 2012),
fotemustine, a drug that has received regulatory approval for the treat-
ment of melanoma in certain European countries (Di Giacomo et al.,
2012), and low-dose cyclophosphamide, with the intent of affecting
regulatory T cells (Pavlick et al., 2014).
The effect of cytokines in potentiating cellular immunity has been
described. Sargramostim (GM-CSF) is one such commercially available
cytokine. A large randomized Phase II trialwas conducted by the EasternFig. 3. Comprehensive overall survival results with ipilimumab in metastatic melanoma.
CI: Conﬁdence interval; OS: Overall survival.Cooperative Oncology Group (ECOG) comparing ipilimumab alone at
10 mg/kg or in combination with standard GM-CSF doses. This trial ac-
crued 250 patients and did not show a difference between arms in re-
sponse rate or in PFS. However, OS favored the combination arm
(median of 17.5 vs. 12.7 months, HR 0.64, p = 0.014). Even more inter-
estingly, the combination arm appeared to be associated with a lower
incidence of high-grade adverse events (AEs). These unusual character-
istics couldwarrant further studies (Hodi et al., 2013a). Other pilot expe-
riences with cytokine combinations include peginterferon alfa-2b
(Kudchadkar et al., 2014), which is approved for the adjuvant treatment
of melanoma, and recombinant interleukin-21 (BMS-982470) (Bhatia
et al., 2013), an experimental compound developed by BMS.
Initial promising results have been reported in a Phase I trial com-
bining ipilimumab with bevacizumab with durable partial responses
(PRs) in 36% of the patients treated (Hodi et al., 2011).
Given the dramatic effect of tyrosine kinase inhibitors (TKIs) in
patients with melanoma and BRAF and/or MEK mutations, the idea to
combine such agents with ipilimumab is very appealing. With their
different kinetics of antitumor effect (rapid vs. slower immediate
tumor shrinkage, limited vs. long-term therapeutic effects for TKIs
and ipilimumab, respectively) a Phase I trial of the combination of
ipilimumab and vemurafenib, the ﬁrst of the BRAF-V600 mutation
inhibitors, was jointly initiated by BMS and Roche/Genentech, the two
sponsors. Unfortunately, the concomitant administration of the two
compounds produced excessive, although reversible, liver toxicity and
the study was stopped (Ribas et al., 2013). Given the availability of
both compounds, as the trial started in November 2011, a rapid commu-
nication of the toxicity encountered was generated, including letters to
the investigators and publications. It is unclear whether a molecular
basis for this interaction exists. Three other TKIs have been tested in
the clinic concomitantly with ipilimumab: dabrafenib alone and also
in a’triplet’ combination with trametinib (Puzanov et al., 2014a) and
BMS-098662, a now-abandoned pan-BRAF inhibitor by BMS (Callahan
et al., 2012), and no unacceptable liver toxicity has been reported to
date.
Another new and exciting chapter in the treatment ofmelanoma con-
sists of the combination of ipilimumabwith other vaccines and/or check-
point inhibitors. Whereas pilot trials in combination with talimogene
laherparepvec (T-VEC), a vaccine that has already reported positive
results as a single agent in a Phase III trial in melanoma (Puzanov et al.,
2014b) and with INCB024360, a small molecule inhibitor of indoleamine
2,3-dioxygenase (IDO) (Gibney et al., 2014), we will cover the combina-
tion of checkpoint inhibitors later in this paper.
3.1.6. Other tumor types than melanoma
3.1.6.1. Prostate cancer. Prostate cancer has provided the setting for a
number of relatively unusual pilot trials with ipilimumab. The initial
study was performed in patients with hormone-refractory prostate
cancer (HRPC)whowere given a single dose of 3mg/kg, with the intent
of evaluating safety and prostate-speciﬁc antigen (PSA) effects
(Small et al., 2007). After this trial reported ≥ 50% reductions of
PSA in 2/14 (14%) patients, subsequent trials pursued different avenues
of development.
A randomized Phase II trial tested again a single dose of ipilimumab
3 mg/kg alone or in combination with androgen ablation. At three
months from initiation of therapy, 30/54 (55%) of patients receiving
the combination and 21/54 (38%) of those receiving a single dose had
undetectable PSA (Tollefson et al., 2010). Another randomized Phase II
trial, this time conducted in the pre-surgical setting, tested the single
dose of ipilimumab 3 mg/kg given early or later in combination with
androgen ablation. At surgery, 5/41 (12%) of the patients receiving
early combination obtained a downstaging of their tumor, as opposed
to 1/32 (3%) of those who received it later (Granberg et al., 2010). A
third, randomized Phase II trial in patients with HRPC tested a standard
induction regimen of ipilimumab 3mg/kg with orwithout a single dose
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(15%) of the patients receiving the combination and 3/24 (12.5%) of
those receiving ipilimumab alone (Small et al., 2006).
The observation in animal models that radiation therapy can induce
responses at a distance from the irradiation portal (the so-called
abscopal effect) has spurred interest in exploring this combination
(Demaria et al., 2005). A Phase I/II trial tested the addition of escalating
doses of ipilimumab (3, 5 or 10 mg/kg) alone or in combination with 8
Gy/lesion (3 or 10 mg/kg). A total of 75 patients with metastatic HRPC
were treated with manageable AEs. Activity by PSA decline and tumor
responsewas observed, without a clear dose–effect or a clear advantage
by the addition of irradiation in the small cohorts treated (Slovin et al.,
2013). Following this pilot experience, a double-blinded Phase III trial
was conducted in metastatic HRPC who had received prior docetaxel,
with the intent to assess the efﬁcacy of ipilimumabwhen added to radi-
ation therapy vs. radiation therapy alone (8 Gy) within a few days prior
to initiation of study therapy. A total of 799 patients were randomized,
and the trial missed the primary endpoint of demonstration of survival
prolongation in the combination arm. Median OS was 10.0 months
in the placebo arm and 11.2 months in the ipilimumab arm (HR 0.85,
p-value 0.0530). Despite this, prespeciﬁed secondary (PFS) and explor-
atory (PSA response rate) endpoints favored the ipilimumab arm.More-
over, a trend in favor of OS beneﬁt was observed also in the prespeciﬁed
subgroup analysis where only patients with visceral metastases
appeared not to beneﬁt from immunotherapy (Kwon et al., 2014).
Notwithstanding the fact that this trial was not positive, the results
observed in patients with less advanced disease increased the expecta-
tions for the results of a second, ongoing Phase III trial that has recently
completed accrual in patients without visceral disease or prior chemo-
therapy exposure (Beer et al., 2013).
Considerable interest in the utilization of immunotherapy in prostate
cancer has been spurred by the approval of sipuleucel-T, the ﬁrst thera-
peutic cancer vaccine to reach the general public (Cheever & Higano,
2011). Indeed, the combination of vaccines with CTLA-4 blockade is
supported by in vivo preclinical data (Hurwitz et al., 2000).
The ﬁrst vaccine to be studied together with ipilimumabwas GVAX, a
cellular vaccine consisting of two prostate cancer cell lines, transduced to
secrete GM-CSF (van den Eertwegh et al., 2012). A total of 28 patients
were treated with ﬁxed doses of GVAX and escalating doses of
ipilimumab (0.3, 1, 3 and 5 mg/kg), and late onset of PSA response was
seen in ﬁve patients (17.8%), lasting in excess of sixmonths. Unfortunate-
ly, two separate Phase III trials of GVAX alone in prostate cancer, one in
symptomatic (Small et al., 2009) and one in asymptomatic patients
(Higano et al., 2009) have failed to demonstrate a survival advantage
over standard therapy, harming the future prospect of this vaccine in
this disease.
A second, somewhat simpler alternative was to administer directly
GM-CSF, which is commercially available, and ipilimumab. A Phase I
trial of this combination has been completed. A total of 36 patients
with HRPC were treated with standard doses of GM-CSF and escalating
doses (0.5 to 10mg/kg) of ipilimumab. Four (11%) of the patients (three
receiving 3 mg/kg, one receiving 10 mg/kg) had a PSA response
(Harzstark et al., 2010).
Another vaccine that is currently in Phase III trials for prostate cancer
is PSA-tricom. This is a poxviral, vector-based vaccine which expresses
transgenes for PSA and T-cell co-stimulator molecules and has been ini-
tially developed by the U.S. NCI. Because of its characteristics, a pilot com-
bination trial with ipilimumab has been conducted. A total of 30 patients
were treated with ﬁxed doses of the vaccine and escalating doses of
ipilimumab (1, 3, 5 and 10 mg/kg). One of the six (17%) chemotherapy-
pretreated patients had a PSA response, as opposed to 14 of the 24
(58%) who were chemotherapy-naïve. The combination did not appear
to exacerbate the known side effects of PSA-tricom (Madan et al., 2012).
3.1.6.2. Lung cancer. Lung cancer has not traditionally been thought of as
an immunotherapy sensitive malignancy. Indeed, several clinical trialsof therapeutic vaccines have failed to demonstrate a signiﬁcant im-
pact upon this disease (Shepherd et al., 2011). However, increased
understanding of the clinical relevance of tumor-inﬁltrating lympho-
cytes (TILs) in lung cancer has contributed to renewed interest in this
therapeutic modality (Rufﬁni et al., 2009). In the case of pulmonary
malignancies such as small cell and non-small cell lung (NSCL) cancer,
where the aggressiveness of metastatic disease might require the rapid
administration of platinum-containing chemotherapy or of targeted
therapies to control tumor growth, the concern was how to integrate
the use of immunotherapy with the existing standard of care, rather
than demonstrating the single-agent role of ipilimumab.
Thus, at the preclinical level, a number of cytotoxic agents usually
utilized in lung cancer were tested in combination with ipilimumab
against ipilimumab alone in a number of experimental solid tumors
(Masters et al., 2009). Then, two large, prospectively randomized,
double-blind, three-arm Phase II trials were conducted testing a
platinum doublet alone, a platinum doublet concomitant with
ipilimumab, and a platinum doublet where ipilimumab was started
sequentially (after two cycles) to chemotherapy. These trials were
conducted in small cell (Reck et al., 2013) and in NSCL cancer
(Lynch et al., 2012).
Both studies met their primary endpoint of prolongation of PFS
according to immune response criteria when the sequential regimens
were compared with standard chemotherapy. In the NSCL trial, the
improvement appeared to be greater in the subset of patients with
squamous cell histology. These results, together with the conduct of a
Phase I trial with the phased regimen in Japanese lung cancer patients
(Nokihara et al., 2013) and with an analysis correlating ipilimumab ex-
posure, tumor shrinkage and survival (Y. Feng et al., 2012) supported
the launching of two large Phase III trials for previously untreated
patients with small cell and with squamous cell lung carcinoma.
3.1.6.3. Additional tumor types. Single-agent trials of ipilimumab have
been reported in renal cell cancer (Yang et al., 2005), pancreatic cancer
(Royal et al., 2009), non-Hodgkin lymphoma(Ansell et al., 2006) and re-
current glioblastoma (Hu et al., 2014; Schaff et al., 2014). A combination
modality trial with TKIs in gastrointestinal stromal tumors (GIST) and
sarcoma (Shoushtari et al., 2014) has also been reported.
A number of relatively unusual combined-modality trials have also
been reported in the neo-adjuvant setting in bladder cancer (Carthon
et al., 2010) and in breast cancer patients undergoing cryoablation
(Diab et al., 2014), concomitantly to radiotherapy and cetuximab in
head and neck cancer (Bauman et al., 2014), to stereotactic radiosurgery
in melanoma (Shoukat et al., 2013), to isolated limb perfusion in
melanoma (Ariyan et al., 2014) as well as in patients relapsing after
hemopoietic stem cell transplantation (Bashey et al., 2005).
Two additional ongoing randomized Phase II studies are currently
addressing the role of ipilimumab administered as maintenance therapy
in patients with gastric or with ovarian cancer who had been initially
treated with standard chemotherapy (ClinicalTrials.gov; NCT01585987;
NCT01611558).
A Phase I trial of ipilimumab has been undertaken in children
with solid tumors, exploring escalating doses of 1, 3, 5 and 10 mg/kg
(Merchant et al., 2012).
3.2. Nivolumab (anti-PD-1)
PD-1 is predominantly involved in regulating the effector phase
of T-cell responses aswell as the non-responsiveness of T cells resulting
from long-termantigen exposure. The fact that cancer cellsmay directly
inhibit an antitumor T-cell response provides tumors an opportunity to
exploit T cells. Expression of PD-1 by tumor-reactive T cells present at
the tumor site can provide for potentially rapid and efﬁcient response
by PD-1 blockade (Pardoll, 2012).
Nivolumab is a fully human IgG4 PD-1 immune checkpoint inhibitor
antibody which is directed to the PD-1 receptor. A comprehensive
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BMS (Wang et al., 2014).
3.2.1. Phase I
A Phase I clinical trial began in October 2006, and 39 patients with
various solid tumors received a dose of nivolumab at 0.3, 1, 3 or
10mg/kg (Brahmer et al., 2010). Remarkably, one patient with colorec-
tal cancer achieved a complete response (CR) to a 3 mg/kg dose, which
lasted in excess of 21months, and two other patients, onewithmelano-
ma and onewith renal cancer, achieved a PRwith doses of nivolumab of
10 mg/kg. Twelve additional patients presented mixed responses or
stable disease (SD). Beneﬁtting patients received multiple doses of
therapy. The drug was well tolerated, with only one patient developing
a grade III colitis, responsive to steroids and inﬂiximab (Lipson et al.,
2013).
A second Phase I trial was begun in October 2008, which provided
for treatment to be repeated at two-week intervals, and grew in size
by the addition of multiple subsequent cohorts to a total of 296 patients
(Topalian et al., 2012). Doses of 0.1, 0.3, 1, 3 and 10 mg/kg were admin-
istered and, as in the case of the ﬁrst Phase I trial, no dose-limiting toxicity
or maximum tolerated dose was determined. As signiﬁcant and durable
antitumor effects were being observed, cohorts of patients with mela-
noma (N = 104), renal (N = 34) and NSCL cancer (N = 122) were
added and expanded. No objective responses were however reported
in 19 patients with colorectal or in 17 patients with prostate cancer.
Cohort expansion was possible also because of the relatively favorable
safety proﬁle, resulting only in 18 (6%) cases of grade III or IV AEs. How-
ever, nine patients developed pneumonitis, and this was severe in three
(1%) of them. Patients received treatment, in the absence of progression
or toxicity, for a maximum of two years. Baseline biopsy specimens
were available in a subset of 42 patients, and only in those patients
whose tumor expressed PD-L1 positivity by a murine anti-human
antibody 5H1 in the tumor and/or at the inﬁltrating T-lymphocytes,
objective responses were observed. The clinical pharmacokinetics
was assessed in both Phase I studies and described as linear, dose-
proportional with a modest (20–44%) inter-subject variability and an
elimination of half-life of 17 to 25 days (Agrawal et al., 2012).
Another Phase I trial, initially limited to patients with previously
treated metastatic melanoma, combined nivolumab at doses of 1, 3
and 10 mg/kg with a multi-peptide (MART-1/gp100/ NY-ESO-1) vac-
cine (Kudchadkar et al., 2012; J.S. Weber et al., 2013). This trial accrued
30 patients, and objective, durable responses were observed at all
dose levels studied. Of note, two of six patients who progressed on
nivolumab responded to subsequent ipilimumab. The relatively good
tolerance to treatment was conﬁrmed, with one case of optic neuritis
and two cases of grade III interstitial pneumonitis observed with
the vaccine combination, and two cases of grade III–IV skin toxicity
observed with nivolumab alone.
3.2.2. Phase II
Whereas, technically speaking, an initial Phase II trial of nivolumab
was not performed, the size of the populations accrued in the Phase I
trials provided suitable information on its efﬁcacy in the tumor types
tested, albeit at different doses.
3.2.2.1. Melanoma. The results of the cohorts of patients with previously
treated, metastatic melanoma have been published separately (Topalian
et al., 2014) and updated with longer follow-up (Hodi et al., 2014). In
this relatively large group of ipilimumab-naïve patients (5% of which
had received a prior BRAF inhibitor), an objective response rate of 32%
was observed, with long durability of responses. Of note, late onset of
responses was less frequent than with ipilimumab, occurring in about
5% of the patients. Additional patients had long-term disease stabilization
and, in this entire group, OS rates of 63% at one year and of 48% at two
years were observedThe ONO Pharmaceuticals Company, located in Japan, had collabo-
rated with BMS from the early days of development of nivolumab.
They conducted a Phase II trial in Japan in melanoma patients who
had been previously treated with DTIC. Patients received 2 mg/kg
every three weeks, and an objective response rate of 23% was observed,
with an additional 49% of patients achieving SD. A median PFS of 5.7
months was reached (Yamazaki et al., 2013). In this trial a relatively
good level of tolerance was reported, with a 17% incidence of grade
III–IV AEs, mostly limited to liver function disorders. These results
were pivotal to the regulatory approval of the drug, granted by the
Japanese Health Authorities on July 4, 2014.
In the context of two separate Phase I trials which tested nivolumab
in combination with a multipeptide vaccine consisting of MART-1,
gp100 and NY-ESO-1 peptides (Kudchadkar et al., 2012; J.S. Weber
et al., 2013) or with ipilimumab (Wolchok et al., 2013b), two cohorts
of ipilimumab-pretreated patients were treated with single-agent
nivolumab at 3 mg/kg or 1 or 3 mg/kg every two weeks, respectively.
Even in these series the efﬁcacy observed was remarkable in terms of
response and their duration.
Although cross-trial comparisons are always to be considered with
caution, these results suggest that PD-1 blockade by nivolumab might
represent one of the most active single-agent treatments for melanoma
(Table 2).
In the trial that combined nivolumab with the multipeptide vaccine
(J.S. Weber et al., 2013), objective responses were seen at all dosage
levels. In 34 patients who had received no prior ipilimumab, eight
(23.5%) objective responses were seen, lasting from 24 to 140+
weeks and seven additional SD exceeding 24 weeks were observed. In
15 patients who had received prior ipilimumab, four (26.6%) responses
and four SD were seen.
As for ipilimumab, a small pilot trial of nivolumab was conducted in
the adjuvant setting in patients with resected stages IIIc or IV (Gibney
et al., 2013). The same multipeptide vaccine studied in the Phase I was
combined with nivolumab at doses of 1, 3 or 10mg/kg, with nivolumab
alone continuing as maintenance every three months after completing
12 doses (24 weeks) of vaccination and nivolumab. Of the 33 patients
enrolled, seven relapsed after a median follow-up of 14months, includ-
ing a patient who had a spontaneous disease regression after a biopsy-
proven relapse.
Altogether, these results have prompted the launch of several Phase
III trials of nivolumab, alone or in combinationwith ipilimumab, in previ-
ously treated and in previously untreated melanoma patients. One such
trial, comparing nivolumab vs. DTIC in previously untreated patients in
countries where ipilimumab for ﬁrst-line therapy had not yet been ap-
proved, has been very recently reported to havemet its primary endpoint
of prolongation of survival (Bristol-Myers Squibb, 2014). The results,
however, have not yet been presented at a scientiﬁc meeting.
3.2.2.2. NSCL cancer. The observation of objective responses in the Phase
I trial of nivolumab and their rapid onset provided the rational for a
large cohort expansion for patients with NSCL cancer. The results
obtained in this group of patients have been recently updated with
longer follow-up (Brahmer et al., 2014). As in the case of melanoma,
no clear-cut dose–effect relationship was observed in patients with
lung cancer with the possible exception of the lowest dose cohort. A
total of 129 previously treated patients were accrued (128 had received
a platinum-based regimen, 36 a TKI). There were 54 patients with
squamous and 74 patients with non-squamous histology (histology
unknown in one case). The objective response rate was 17% across all
doses (24% at the 3 mg/kg every two weeks level) with an additional
10% of SD. There was no difference in response rates between histolo-
gies, and the vast majority of responses occurred rapidly (within 16
weeks) and had a median duration of 74 weeks. Median PFS was 2.3
months and median survival 9.9 months. Objective responses were
seen in 11% (4/36) of patients previously treated with TKIs, and in 17%
(2/12) of patients with a known EGFR mutant status.
Table 2
Single-agent activity of nivolumab in previously treated patients with metastatic melanoma (Phase I and II trials).
Author Dosage (mg/kg) Prior Rx No. Pts. CR + PR CR + PR + SD Durability (median, months)
Hodi 0.1-10
q 2 weeks
100%
65% immuno Rx
5% BRAF-Ia
107 34 (32%) 41 (38%) Response: 24.9
PFS: 3.7
OS: 17.3
Yamazaki 2
q 3 weeks
100%
100% DTIC
35 8 (23%) 25 (73%) PFS: 5.7
Weber 3
q 2 weeks
100%
100% ipilimumab
38 10 (26%) 17 (45%) Response: not reached
(from 12+ to 48+ weeks)
Wolchok 1–3
q 2 weeks
100%
100% ipilimumab
6% BRAF-I
30 6 (20%) 13 (43%) –
BRAF-I: BRAF inhibitor; CR: Complete response; DTIC: Dacarbazine; PR: Partial response; Pts: Patients; RX: Therapy; SD: Stable disease.
a BRAF-I.
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viously untreated patients with NSCL cancer (Gettinger et al., 2014).
A total of 20 patients were given a dose of 3 mg/kg every two weeks.
Six of themhad received prior adjuvant or neo-adjuvant systemic treat-
ment. Half of them had a non-squamous histology. None had EGFR
mutations. Two CRs and four PRs were obtained (response rate: 30%)
and the median duration of response was not reached at the time of
reporting, ranging from 23.7 to 71.4+ weeks. Similar response rates
were seen in squamous and non-squamous histologies. Again, the
majority of the responses occurred rapidly, within 12 weeks.
In both studies of nivolumab monotherapy in lung cancer the toler-
ability was good: grade III–IV AEs occurred in 14% of the pretreated and
in 10% of the untreated patients. Of note, three treatment-related
deaths, all involving pneumonitis, occurred in the 129 pretreated
patients. In this population, altogether, there were seven cases (9%)
of pneumonitis. In the previously untreated study, no pneumonitis
occurred.
Given the level of activity observed, combination trials of nivolumab
with standards of care for lung cancer have been initiated. Platinum
(cisplatin or carboplatin) doublets with gemcitabine or pemetrexed or
paclitaxel have been concomitantly administered to nivolumab at
10 mg/kg, given every three weeks to parallel the chemotherapy regi-
mens (S.J. Antonia et al., 2014). A total of 56 previously untreated pa-
tients entered the trial, and objective responses ranging from 33 to
47% were observed with the various combinations. Medial duration of
response ranged from 23.9 weeks to not reached. Additional SD was
seen in 27 to 58% of the patients. Of note, the combination with
carboplatin and paclitaxel required a reduction of the nivolumab dose
to 5 mg/kg due to toxicity. Median PFS ranged from 21 to 31 weeks,
and median survival from 50.5 weeks to not reached. Grade III–IV pneu-
monitis was seen in four patients (7%).
The combination with erlotinib is very appealing, as preclinical data
indicate that blocking the PD-1 pathway in EGFR mutant tumors pro-
duces in vivo tumor regressions and survival prolongation (Akbay
et al., 2013). The clinical trial added nivolumab 3 mg/kg every two
weeks to erlotinib 150 mg/day and reported four objective responses
(19%) and nine SD (43%) in 21 patients, 20 of whom were erlotinib-
pretreated. Responses lasted from 60.1 to 72.3+ weeks. Median PFS
was 29.4 weeks (Rizvi et al., 2014). Of importance, the combination of
nivolumab with a TKI such as erlotinib did not produce the same type
of liver toxicity that had been previously reported with the ipilimumab
and vemurafenib concomitant administration.
Because of the remarkable results observed in these early experiences,
Phase III trials of single-agent nivolumab vs. standard chemotherapy have
been initiated both in previously treated and in previously untreated
patients, and in both NSCL cancer histologic subtypes.
3.2.2.3. Renal cell carcinoma. The small cohort of patients with renal cell
cancer accrued to the Phase I trial of nivolumab consisted of 34 patients
treatedwith doses of either 1 or 10mg/kg every twoweeks (Drake et al.,
2013). Objective responses were seen at both doses, with 10 (29%)responding and nine additional patients achieving SD. Median duration
of response was 12.9 months, and OS, in this group of pretreated
patients, was 70% at one year. Six percent of the patients presented
grade III–IV respiratory disorders and 6% hypophosphatemia.
Two randomized dose-ranging Phase II trials of single-agent
nivolumab were subsequently carried out. Both utilized an every three
weeks dosing regimen. The ﬁrst of these trials accrued previously treat-
ed patients with at least one antiangiogenic therapy, and randomized to
three arms at 0.3, 2 or 10 mg/kg (Motzer et al., 2014). A total of 168
patients were accrued, and the primary endpoint of the study, PFS,
appeared to favor the two higher-dose arms (medians 2.7, 4.0 and 4.2
months, respectively, p = 0.9). Response rates (20, 22 and 20%) were
similar; however, OS also appeared to favor the two higher-dose arms
(medians 18.2, 25.5 and 24.7 months, respectively). Grade III–IV AEs
were 5%, 17% and 13%, with no severe pulmonary toxicity observed.
Whereas this study did not conclusively demonstrate a dose effect for
nivolumab, the survival results observed in each armwere very promis-
ing for a population of heavily pretreated patients.
The second randomized Phase II trial also accrued 67 previously
treated patients who were given either 0.3, 2 or 10 mg/kg every three
weeks. An additional, non-randomized cohort of 23 previously untreat-
ed patients was given nivolumab at 10 mg/kg (Choueiri et al., 2014).
This trial required the availability of tumor specimens for biomarker
assessment. Once again, the higher-dose arms presented numerically
superior results in terms of PFS (18, 32 and 49%, respectively, at 24
weeks) and of objective response rates (9, 23 and 22%, respectively).
In the treatment-naïve arm, PFS at 24 weeks was 45% and the response
rate 13%. Grade III–IV AEs were 18% in the pretreated and 8% for the un-
treated cohort. A single case of grade III–IV pneumonitis was observed,
in the pretreated group.
An additional trial for patients with renal cancer explored the com-
bination of nivolumab with two TKIs with activity in this disease, either
sunitinib or pazopanib (Amin et al., 2014). Patients who had received
prior treatment with pazopanib were assigned to be given sunitinib at
standard doses plus nivolumab at 2 mg/kg every three weeks, escalated
to 5 mg/kg. A total of 33 patients were accrued, with one CR and 16 PR
(52%) with a median duration of 37.1 weeks. An additional 10 patients
had SD. Median PFS was 48.9 weeks. Grade III–IV hepatic AEs were
18% for ALT and 9.1% for AST increases, three patients presented renal
function abnormalities. One patient had a grade III–IV pneumonitis. Pa-
tientswhohad received prior treatmentwith sunitinibwere assigned to
be given pazopanib at standard doses plus nivolumab at 2 mg/kg every
three weeks. No dose escalation occurred in this group, due to gastroin-
testinal (grade III–IV in 20%) and hepatic (grade III–IV elevation of ALT
and AST in 20%) AEs. In the 20 patients treated, nine (45%) PR and
seven additional SD were observed. Median duration of response was
30.1 weeks and median PFS 31.4 weeks. In consideration of these
results, a Phase III trial was initiated in renal cell cancer patients who
had been previously treated with ≤ 2 prior antiangiogenic therapies
and ≤ 3 prior regimens. They are being randomized to nivolumab
3 mg/kg every two weeks or oral daily everolimus at standard doses.
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only in one other solid tumor type, ovarian cancer (Hamanishi et al.,
2014). A total of 13 platinum-resistant patients have been accrued to a
dose-escalation trial in Japan. Doses of 1 and 3 mg/kg every two
weeks were being studied. A total of three PR (23%) with duration of
4+, 5 and 10+ months were observed, and an additional SD occurred
in four patients. A single case of severe AE was seen, with fever, disori-
entation and gait disturbance.
3.3. Combination of ipilimumab and nivolumab
Although both ipilimumab and nivolumab disrupt the inhibitory in-
teraction of CTLA-4 and PD-1 with their respective ligands, their biolog-
ical activity appears to be complementary. While the anti-CTLA-4 effect
of ipilimumab may be more prominent in the early stages of the T-cell
activation perhaps at the lymphnode, other activities of CTLA-4 blockade
may complement the effect of PD-1 blockade. Regulatory T-cell depletion
at the tumor sitemay occur aswell as the removal of the suppressive role
of CTLA-4 in TILs (Ahmadzadeh et al., 2009). The anti-PD-1 effect of
nivolumab is likely to be more prominent in the tumor microenviron-
ment, where PD-1 expression is very pronounced in TILs (Fig. 4).
In vivo experiments carried out at BMS and elsewhere have
conﬁrmed the enhanced antitumor effect of the dual CTLA-4 and PD-1
blockade in mouse models (Korman et al., 2007; Curran et al., 2010;
M. Selby et al., 2013).
3.3.1. Combination in melanoma
With this foundation, a clinical trial combining the two antibodies in
patients with melanoma was initiated in December 2009 (WolchokFig. 4. Rationale for combining ipilimumab and nivolumab. CTLA-4: Cytotoxic T-lymphocyte an
receptor.et al., 2013b). This was, to our knowledge, the ﬁrst clinical experiment
in combining two checkpoint inhibitory molecules.
The initial dose-escalation design planned for ﬁxed doses of
ipilimumab (3mg/kg) to be combinedwith increasingdoses of nivolumab
(0.3 mg/kg in 14 patients, 1 mg/kg in 17 patients, and 3 mg/kg in 6
patients). At the highest dose level, 3 of 6 patients had asymptomatic,
but persistent, grade III–IV serum lipase elevations. Thus a de-escalated
dose-level group (ipilimumab 1 mg/kg and nivolumab 3 mg/kg) of 16
patients was added.
The lower-dose cohorts presented grade III–IV AEs in 46% of the
patients, with hepatic (15%), gastrointestinal (9%) and renal (6%) events
being most common. A single case of pneumonitis and one of uveitis
were also reported. The antitumor effects observed were impressive:
in the 53 patients treated (38% had prior immunotherapy, 6% prior
BRAF inhibitors), ﬁve CR and 16 PRs were observed (39.6%). Additional,
unconﬁrmed PR (two patients), immune-related PR (four patients) or
SD lasting ≥ 24 weeks (four patients) were also observed.
Equally impressive was the rapidity of the tumors shrinkage (with
the vastmajority of responses occurring before 24weeks from treatment
initiation) and the depth of the effect,with 16 patients (including theﬁve
CRs) experiencing a reduction of ≥ 80% of their initial tumor burden
within 12 weeks. As minimal residual nodules were not systematically
biopsied, it is not clear whether there were additional CRs among the
PRs who had a N 80% tumor shrinkage. What is clear is that these
tumor shrinkages were sustained for a long time.
The long-term results of this trial have been recently updated (Sznol
et al., 2014) with the addition of yet another cohort of 40 evaluable pa-
tients given nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg. Unlike
for the initial cohorts, for this additional cohort ipilimumab wastigen 4; MHC: Major histocompatibility complex; PD-1: programmed death-1; TCR: T-cell
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the patients were pretreated and 7% had had a BRAF inhibitor. In this
cohort, four CR and 13 PRs (42.5%) were observed, with four additional
SD. Tumor reduction by N 80% was seen in 28% of the patients.
Safety-wise, grade III–IV AEs occurred in 61% of the patients in the
new cohort, with gastrointestinal (20%), skin (15%) and hepatic (12%)
AEs being the most frequent. Two cases each of severe pneumonitis
and uveitis were also seen.
In the combined initial series and the added cohort, the durability of
the effect was remarkable: median duration of response was not
achieved, with only ﬁve relapses observed. Even more remarkable, the
updated OS results of the initial cohorts indicated that 85% at one year
and 79% at two years of the patients survived, with a median survival
of 40 months and amedian PFS of 27weeks. OS data are not yet mature
in the added cohort, but median PFS was 37 weeks.
The results of this study have prompted the initiation of two ran-
domized trials of the combination in previously untreated patients
with metastatic melanoma. In the ﬁrst trial, the combination is being
compared to single-agent ipilimumab, with response rate as the prima-
ry endpoint. In the second, larger Phase III trial, each individual agent is
being compared with the combination, with OS as the primary end-
point. The regimen selected for both trials utilizes a dosage of 3 mg/kg
of ipilimumab and of 1 mg/kg of nivolumab given every three weeks,
with ipilimumab discontinuation after four induction doses. At the time
of this writing, both trials have been fully accrued (ClinicalTrials.gov;
NCT01927419 [CheckMate 069]; NCT01844505 [CheckMate 067]).
3.3.2. Combination in NSCL cancer
In lung cancer, both squamous and non-squamous histologies were
accrued, and patients had received no prior treatment (S.A. Antonia
et al., 2014). Two regimenswere explored, onewith 3mg/kg ipilimumab
plus 1 mg/kg of nivolumab (N = 24) and the other with 1 mg/kg of
ipilimumab plus 3 mg/kg of nivolumab (N = 25). Objective responses
were seen with the ﬁrst regimen in three (13%) of the patients, with
seven additional SD. Median PFS was 16.1 weeks. With the second
regimen, objective responses were ﬁve (20%), with additional nine SD.
Median PFSwas 14.3weeks. Grade III–IV treatment-related AEs occurred
in 49% of the patients across treatment arms. Grade III–IV pneumonitis
occurred in three (6%) patients and was reversible with steroid treat-
ment and discontinuation.
With the small number of patients available, nomajor differences in
safety or efﬁcacy were apparent across treatment arms. Additional
experience with this combination in the treatment of lung cancer
needs to be gathered.
3.3.3. Combination in renal cancer
In renal cancer, both untreated and pretreated patients were ran-
domized to receive either one of the two regimens described above
(Hammers et al., 2014). Again, nivolumab single-agent 3 mg/kg every
two weeks was administered after the completion of the four induction
courses with the combination.
In the arm with 3 mg/kg ipilimumab and 1 mg/kg nivolumab, 23
patients were accrued (18 pretreated). One CR and 10 PRs (47%) were ob-
served, with an additional eight SD. Median duration of response was not
reached, and median PFS was 38.3 weeks. In the arm with 1 mg/kg
ipilimumab and 3 mg/kg nivolumab, 21 patients were accrued (17
pretreated).NinePR (43%),with additionalﬁve SDswere observed.Median
duration of response was 31.1 weeks, and median PFS was 36.6 weeks.
Also in this trial, responses appeared to occur rapidly, within six
weeks in half of the responders, and only four relapses have occurred.
Grade III–IV AEs occurred in 61% of the patients with the ﬁrst regi-
men and 29% with the second. Hepatic (26%) and gastrointestinal
(17%) grade III–IV AEs were seen in the latter; whereas no hepatic and
a single case of gastrointestinal (5%) grade III–IV AEs were seen in the
former. Even if preliminary, these results offer the opportunity to
study a novel immunotherapy regimen highly effective in this disease.3.4. BMS-986015 (anti-LAG-3)
The theme of early combination of immune checkpoint inhibitors
is being pursued also in the case of the clinical development of BMS-
986016, an anti-LAG-3 monoclonal antibody.
As previously discussed for CTLA-4 and PD-1, LAG-3 and PD-1 can
exert functionally distinct effects on CD8+ T-cells. Both PD-1 and
LAG-3 have been observed to be expressed on CD8+ T cells which
have become chronically activated but non-functional in the presence
of a viral infection (Grosso et al., 2009; Wherry, 2011). In addition,
CD8+ effector cells in TIL in murine models have also been observed
to express both PD-1 and LAG-3 (Woo et al., 2012). Blockade of PD-1
and LAG-3 can revert this condition, which has been referred to as
‘lymphocyte exhaustion.’
The recently initiated Phase I clinical trial will ﬁrst administer
BMS-986016 alone, at escalating doses, in order to obtain a pharma-
cological and clinical characterization of the drug. Subsequently
nivolumab will be added, including patients with solid tumors who had
been previously exposed to checkpoint inhibition (ClinicalTrials.gov;
NCT01968109).3.5. Urelumab (anti-CD137)
Urelumab was the ﬁrst agonistic checkpoint antibody that entered
clinical trials (Logan et al., 2008; Sznol et al., 2008). Dosages of 0.3, 1,
3, 6, 10 and 15 mg/kg every three weeks were studied in the dose-
escalation phase (24 patients), and then in a randomized phase of
three doses (1, 3, 10 mg/kg) in 97 additional patients. Four PRs and
ﬁve SD were observed in 47 patients with melanoma, ﬁve SD in 26
patients with renal cell carcinoma, and no activity in 24 patients with
ovarian cancer.
However, the program was stopped because of the emergence of
excessive liver toxicities at the higher doses (Li & Liu, 2013). This liver
toxicity may be a class effect since it has also been described in mouse
models of CD137 agonism (Dubrot et al., 2010).
Clinical trials have been reinitiated at lower doses and are currently
ongoing. A single-agent trial (Melero et al., 2013b) and a combination
trial with rituximab (Kohrt et al., 2013) are being conducted, with
special emphasis on lymphomas because of the demonstrated ADCC
enhancement property of urelumab (Kohrt et al., 2012).3.6. BMS-936559 (anti-PD-L1)
The monoclonal antibody BMS-936559 was the ﬁrst compound
directed to an immunomodulatory ligand which entered the clinic
(Brahmer et al., 2012). Of note, this compound was studied by BMS in
parallel with nivolumab, the PD-1 receptor directed monoclonal.
Beginning in April 2009, 207 patients were accrued to a Phase I trial
that studied escalating doses of 0.3 (three patients), 1 (37 patients), 3
(42 patients) and 10 (125 patients) mg/kg. No dose–effect was demon-
strated, with rare grade III–IV AEs observed in 5% of the patients at each
dose (except for 0.3 mg/kg). Doses were repeated every two weeks.
Objective responses were seen in melanoma, with 9/52 (17%) PRs and
14 SD; in NSCL cancer, with 5/49 (10%) PRs and six additional SD; in
renal cell carcinoma with 2/17 (12%) PRs and seven additional SD;
and in ovarian cancer, with 1/17 (6%) PR and three additional SD. No
activity was seen in 18 patients with colorectal, 14 with pancreatic,
seven with gastric and four with breast cancer. Responses and disease
stabilization were durable, and PFS rates at 24 weeks ranged from 12
to 41%. On the basis of the results observed in the parallel Phase I trial
of nivolumab the authors indicated, with the limitation of the lack of a
direct randomized comparison between the two compounds, that the
observed frequency of objective responses appeared somewhat lower
with the anti-PD-L1 monoclonal than with nivolumab.
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Exploring new areas of research offers the challenge of facing novel
and/or unexpected aspects. The development of immuno-oncology
treatments presented clinical characteristics that sometimes deviated
from the known paths of more traditional chemotherapy and even
targeted therapy, both in terms of safety and efﬁcacy.
4.1. Safety
The vast majority of the AEs appearing during immune modulation
can be directly related to the mechanism of action of these agents,
and, thus, referred to as ‘on target’ events.
4.1.1. Immune-mediated and immune-related AEs (ipilimumab)
The fact that the stimulation of the immune system could produce
both antitumor and ‘auto-immune’ events was recognized soon after
the beginning of the clinical trials with ipilimumab. These AEs have
been deﬁned with various terms, with the one adopted in the current
label of Yervoy® (ipilimumab) (Drugs@FDA, 2014) being ‘immune-
mediated adverse reactions’ and the most frequently used term in
the literature being ‘immune-related AEs.’ The difference between the
two deﬁnitions consists of the fact that ‘immune-mediated adverse re-
actions’ refers to a retrospective assessment where the inﬂammatory
nature of the events is documented, directly or indirectly by the con-
sideration of adjacent events and information (e.g., recovery after
anti-inﬂammatory treatment) and can thus collapse multiple events
representing the evolution of the same episode. On the contrary, ‘im-
mune-related AEs’ refers to a prospective data collection approach
that covers events that are presumably related to themechanismof action
and thus can prompt the investigator to institute anti-inﬂammatory
guidelines early in the course of the event. Whereas the former approach
is more accurate, the latter might be more practical, even if it could over-
estimate the nature of the event. Regardless of the terminology, these
events present the common denominator of a proliferation of activated
T-cell and pro-inﬂammatory reactions in normal organs and tissues.
The most common severe AEs observed with ipilimumab (so far the
most largely studied immune checkpoint inhibitor) are enterocolitis,
hepatitis, dermatitis, endocrinopathy, and neuropathy. Enterocolitis,
often starting with diarrhea symptoms, if not properly recognized and
managed, could worsen and lead to bowel perforation and, indeed,
these severe toxicity episodes occurred in the early clinical trials with
ipilimumab (Beck et al., 2006). Histopathologic examination of colonic
biopsies in patients with grade II or more diarrhea documented the
presence of mixed inﬂammatory cell inﬁltrates in the lamina propria
and foci of cryptitis, crypt abscesses, glandular destruction, and erosion
of the mucosal surface (Berman et al., 2010).
A comprehensive review of completed trials of ipilimumab at
various doses in melanoma (14 trials with 1498 patients) reported an
incidence of immune-related gastrointestinal AEs, grouped from differ-
ent terms, of 33% (any grade) and 9% (grade III–IV), the latter including
ﬁve cases of perforation (two lethal). One additional case of lethal
gastrointestinal toxicity was reported, without perforation (Ibrahim
et al., 2011). Another comprehensive review of the time of onset and
resolution of AEs (limited to Phase II trials of ipilimumab inmelanoma)
reported a median time to onset of any gastrointestinal AE (except
for grade I) of 6.6 weeks, duration of 2.1 weeks and resolution of 2.3
weeks (Lebbe et al., 2008).
Hepatitis, consisting of liver function abnormalities potentially
leading to hepatic failure, could also be related to an immunological
activation. Also for the liver, biopsies documented an inﬂammatory
pattern of injury that was non-speciﬁc and similar to that observed in
acute viral and autoimmune hepatitis (Kleiner & Berman, 2012). The in-
cidence of immune-related hepatic AEs was 1.6% (any grade) and 1.1%
(grade III–IV) with two lethal cases of hepatic failure. Three additional
cases of lethal hepatic failure could not be attributed to an immune-mediated causality. Median time to onset was 6.7 weeks, median dura-
tion 3.6 weeks and median time to resolution was 4.0 weeks.
Dermatitis included skin rash and pruritus, with a course beginning
usually with a discrete pruritic and erythematous papular aspect and
progressing to coalescing, scaled plaques (Jaber et al., 2006). The inci-
dence of immune-related dermatologic AEs was 44.9% (any grade)
and 2.6% (grade III–IV). Time to onset was 3.6 weeks, duration 3.3
weeks and time to resolution 6.1 weeks.
Alterations of endocrine function have been reported after treat-
ment with ipilimumab, most often consisting of hypopituitarism, hypo-
thyroidism and adrenal insufﬁciency, in order of frequency. Indeed, the
expression of the CTLA-4 receptor in the pituitary gland has been
reported (Iwama et al., 2014). Clinical symptoms of hypopituitarism
can include headaches, asthenia and decreased libido. Swelling of the
gland has been documented by MRI (Dillard et al., 2010; Carre et al.,
2012). Hypothyroidism and adrenal insufﬁciency can also present a
subtle onset, but cannot be readily documented by radiologic testing.
The incidence of endocrine immune-related AEs was 4.5% for any
grade and 2.3% for grade III–IV. Time to onset was slower and duration
longer than with other immune-mediated AEs: median of 9.2 weeks
to onset, mediation duration of 20.6 weeks. Time to recovery has been
reported to be 20.1 weeks; however, it must be realized that endocrine
abnormalities, whereas having the tendency to be controlled by re-
placement therapy, could often require continuation of such supportive
treatment.
Neurologic AEs have been grouped under the terms of peripheral
neuropathy, sensory and/or motor. However, given the extensive prior
treatment administered to the patients in the safety database, it is
difﬁcult to attribute them to a clear immune-mediated mechanism.
Thus, whereas an overall 6% incidence of neuropathy has been reported,
three cases could be deﬁnitely attributed to an immunological mech-
anism. Two of these cases were low-grade, but one lethal case of
Guillain–Barré syndrome has been reported (Wilgenhof & Neyns,
2011).
Immune-mediated adverse reactions can also affect almost every
organ. Thus, rare cases of uveitis, non-infectious pericarditis (Ibrahim
et al., 2011), sarcoidosis (Vogel et al., 2012), lupus nephritis (Fadel
et al., 2009), hemophilia (Delyon et al., 2011) and myasthenia gravis
(Johnson et al., 2014b) have been reported in the literature. Whereas
this is not intended to be a comprehensive list of potential AEs, it does
underline that unusual immune-mediated events can always occur,
and that they will demand a speciﬁc management.
Of note, in the case of ipilimumab, treatment-related AEs and
immune-related AEs observed in patients with advanced melanoma
were generally similar to those accrued to the Phase III trial in prostate
cancer, notwithstanding the particularly heavily pretreated characteris-
tics of the patients accrued to the latter trial and the high ipilimumab
dosage (10 mg/kg) utilized along with maintenance therapy (Beer
et al., 2014) (Table 3).
Elderly patients with melanoma (Chandra et al., 2013) also do not
seem topresent a signiﬁcant difference in the safety proﬁle as compared
to younger patients.
4.1.2. Management of immune-related AEs (ipilimumab)
Given the nature of the AEs observed in the early trials of ipilimumab,
a number of speciﬁc guidelines aimed at the prevention and/or treatment
of these AEs were progressively introduced in the clinical development
program (Chin et al., 2008).
Themajority of the algorithms introduced provided for careful mon-
itoring at the beginning of treatment, early introduction of low-dose
steroids in the presence of low-grade, but persisting toxicity, increase
of steroid dosage in the case of no improvement and introduction of
alternative immuno-suppressive therapy (such as inﬂiximab) in the
case of further resistance to steroid treatment.
This type of approach requires a particular level of education and fa-
miliarity by both physicians and nurses who might be used to different
Table 3
Immune-related or selected AEs reported with ipilimumab or nivolumab (%).
Ibrahim et al. (2011) Beer et al. (2014) Hodi et al. (2013b)
Ipilimumab
(Melanoma, n = 1498)
Ipilimumab
(Prostate, n = 393)
Nivolumab
(Various, n = 306)
Any grade Grade. III–IV Grade V Any grade Grade III–IV Grade V Any grade Grade III–IV Grade V
Any irAE or selected AEs 64 18 [9]a 63 26 [2] 46 6 [3]
Dermatologic 45 3 – 35 1.0 – 25 [1] –
Gastrointestinal 33 9 [3] 41 18 [2] 14 1.0 –
Endocrine 5 2 – 5 2 – 10 1.0 –
Hepatic 1.6 1.1 [2] 10 5 – 6 1.3 –
Ocular 1.3 0.4 – – – – – – –
Neurologic [2] – [1] 2 – – – – –
Pulmonary – – – – – – 6 2 [3]
Renal – – – – – – 2 [1] –
AEs: adverse events; irAEs: immune-related adverse events.
a In brackets: absolute numbers.
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Thus, effectiveness of these guidelines was also monitored and reported
(Richards et al., 2009). The analysis concluded that a reduction of the rate
of gastrointestinal perforation was achieved with the implementation of
these guidelines.
The experience accumulated during the course of the clinical devel-
opment program was utilized in implementing a Risk Evaluation and
Mitigation Strategies (REMS) program after the regulatory approval of
ipilimumab.
Another speciﬁc trial was carried out in the attempt of reducing gas-
trointestinal tract inﬂammation by administering a topically active,
non-reabsorbable steroid, budesonide (Weber et al., 2009). Unfortu-
nately that trial failed to show a protective effect in the budesonide arm.
In the initial clinical trials, concern was raised from investigators
over whether corticosteroids would dampen antitumor immunity.
Three analyses conducted in patients with metastatic melanoma
accrued to Phase II trials (Amin et al., 2009) and to the two Phase III trials
in previously treated (Lorigan et al., 2010) and in previously untreated
patients (Baurain et al., 2012) help dispel this notion, reporting similar
long-termoutcomes in the steroid-treated and steroid-untreated groups.
Based on an initial report linking toxicity to response (Downey et al.,
2007), BMS has explored whether there is an association between OS
and immune mediated toxicity. Analyses conducted in two different
series of patients with metastatic melanoma showed no signiﬁcant
correlation between OS and the occurrence of immune-related AEs
(Lutzky et al., 2009; Di Giacomo et al., 2013).
4.1.3. Long-term safety (ipilimumab)
The activation of the immune system achieved with inhibitory
checkpoint blockade poses also the question of potential long-term
effects. This consideration is compounded by the fact that long-term
survivorship can be attained with this form of treatment. Analyses of
the long-term survivors in the twometastatic melanoma Phase III trials
of ipilimumab have thus been conducted.
In the trial in previously treated patients, 94 patients who sur-
vived ≥ 2 years were identiﬁed (16 with placebo, 24 with ipilimumab
alone and 54with the combination). In the placebo arm, a single patient
presented grade I vitiligo during long-term follow-up. In the ipilimumab
arm, a single patient presented grade I vitiligo and grade II hypothyroid-
ism. In the combination arm, three patients presented grade I vitiligo,
one patient grade II hypogonadism, and one patient grade III colitis.
This patient also presented grade I diarrhea and grade II proctitis, and
the AEs recovered partially after 147 days (McDermott et al., 2013).
In the trial of previously untreated patients, 112 survivors for
≥ 2 years were identiﬁed (44 randomized to DTIC, 68 to DTIC plus
ipilimumab). In the DTIC arm, cases of amylase increase, lipase increase,
and low-grade diarrhea (one each) were seen. In the combination arm,
three cases of pruritus (one severe), two of skin rash (one severe), andone of mild skin hypopigmentation were observed. In addition, there
was one case of low-grade liver function test elevation. Of note, all of
these events, except for one low-grade pruritus and one with skin
hypopigmentation, occurred in patients still receiving ipilimumab
maintenance treatment (Thomas et al., 2012). Altogether, and in a fairly
sizeable group of patients, these analyses reassure on the long-term
safety of the compound. Interestingly, the observation of vitiligo is related
to the persisting presence of an activated immunologic system.
4.1.4. Selected AEs (nivolumab)
A somewhat different approach to the one adopted to assess AEs in
patients given ipilimumabwas adopted for nivolumab. Clinically impor-
tant AEs were captured prospectively, independent of causality, and
organized into organ-deﬁned categories (i.e., gastrointestinal tract, skin,
liver, etc.). Certainly the mechanism of action of the two compounds
points to the potential for similar toxicity-inducing mechanisms.
In the case of nivolumab, however, the incidence of selected AEs and
their severity appeared inferior to that reported with ipilimumab
(Table 3) even with long-term safety assessment of the Phase I group
of patients who, contrary to the ipilimumab patients, could continue
to receive nivolumab for two years (Hodi et al., 2013b). Whereas the
data presented in Table 3 do not intend to compare the three series
of patients (which address different populations of patients and utilize
different doses and regimens), their display allows for an initial quanti-
tative and qualitative early assessment of the results that will be ulti-
mately resolved by the ongoing randomized Phase III trials.
In general, the type of AEs observed with nivolumab are consistent
with those observed with ipilimumab, with the sole exception of pneu-
monitis and nephritis. Pneumonitis has been observed in most trials of
nivolumab, with incidences ranging from 3 to 6% (any grade) and from
0 to 2% (grade III–IV).Higher incidences of 14%and7%, however,were ob-
served in the pilot trial combining nivolumabwith chemotherapy in lung
cancer. Nephritis, mostly documented by increases of serum creatinine,
occurred in 2% of the cases (any grade) and in a single patient (grade
III–IV) during long-term follow-up of the Phase I trial (Hodi et al.,
2013b). The AEs that occur during nivolumab treatment can be managed
by utilizing the same algorithm established for ipilimumab, and revers-
ibility has been achieved.
4.1.5. Other safety aspects of immune-checkpoint modulation
The occurrence of dose-limiting hepatic toxicitywhen administering
ipilimumab in combination with vemurafenib and when administering
single-agent urelumab at high doses has been previously discussed. Of
note, also the combination of ipilimumab and DTIC appears to produce
a marked increase of hepatic, but not of gastrointestinal, toxicity as
compared to the historical experience of single-agent ipilimumab at
the same dose (F.Y. Feng et al., 2012).
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pounds at the beginning of clinical development such as BMS-986016
(anti-LAG-3) and of low-dose urelumab (anti-CD137). However, in
the case of BMS-936559 (anti-PD-L1), the safety proﬁle initially
observed in the Phase I trial conﬁrms the suggestion of a low level of
toxicity when blocking the PD-1/PD-L1 pathway.
The interest emerging on the combination of ipilimumab and
nivolumab is intensely scrutinizing both the efﬁcacy and the safety
characteristics of this innovative approach in various tumor types. The
current information available is summarized in Table 4. Again, whereas
the data are still somewhat early, it is conceivable that this synergistic
combination could elicit both increased efﬁcacy and toxicity. It would
appear that, at least qualitatively, immune-related AEs are in line with
what was previously observed with each individual checkpoint inhibi-
tor. The possible exception is represented by increases of serum lipase
and amylase that, albeit asymptomatic, had not beenpreviously reported
with either agent.
The pilot nature of these trials, utilizing different dosages and regi-
mens of the combination, is still a work in progress. However, it is also
conceivable that different tumor types and/or different stages of disease
might require different dosing approaches. This is likely to hold true also
for other future combinations of other immune checkpoint modulators.
4.2. Efﬁcacy
When the tumor cell is not directly targeted by anticancer therapy,
as in the case of immunomodulatory interventions, the kinetics of
efﬁcacy can be expected to be different.
4.2.1. Immune-related response criteria
Early in the clinical development of ipilimumab it became evident
that certain patients would not present the usual pattern of tumor
shrinkage familiar to the oncologists when administering cytotoxic,
hormonal or targeted therapy. Not only did certain patients require
longer time tomount an immunological reaction, and therefore an anti-
tumor effect, but also, in certain cases, tumor lesion growth and even
the appearance of new lesions would precede the antitumor response.
Thus, patients who would be classiﬁed as having progressive disease
by standard WHO criteria or Response Evaluation Criteria In Solid
Tumors (RECIST) could, instead, be receiving beneﬁt from treatment.
Although the resection of certain tumor nodules increasing in size
was carried out, and it revealed that such an increase was in fact often
due to TIL infarction, this could not account for every single case of
pseudo-progression. Spurred by the experience of patients returning
to the clinic with shrinking or disappearing tumors after an initial eval-
uation of progression, protocolswere amended to provide for additional
tumor evaluation after progression anda systematic reviewof the kinetics
of response was carried out. The large database of ipilimumab wasTable 4
AEs reported with ipilimumab and nivolumab combinations (%) (all cohorts combined).
Sznol et al.
(2014)
S.A. Antonia et
al. (2014)
Hammers et al.
(2014)
Melanoma
(n = 94)
NSCLC
(n = 49)
Renal
(n = 44)
Any
grade
Grade
III–IV
Any
grade
Grade
III–IV
Any
grade
Grade
III–IV
Dermatologic 77 9 24 4 39 –
Gastrointestinal 39 14 41 18 23 14
Endocrine 19 3 6 4 25 –
Hepatic 22 14 10 8 15 5
Ocular 4 3 – – – –
Pulmonary 4 2 12 6 7 –
Renal 3 3 – – 11 –
Lipase 21 15 14 8 – –
Amylase 17 6 12 4 – –utilized, and this resulted in the proposal for establishing new immune-
related response criteria (Wolchok et al., 2009).
Different patterns or kinetics of tumor response were described, and
this allowed the possibility of identifying a group of about 10% of
patients who would have not met standard criteria for clinical beneﬁt
(CR or PR or SD) but who presented long-term survival outcomes simi-
lar to those assessed as beneﬁtting by standard criteria.
It is not clear whether all immunological interventions will produce
the same behavior in tumor response and, perhaps, the verymechanism
of T-cell activation that ipilimumab producesmight havemagniﬁed this
effect. However, the same type of phenomenon has been observedwith
single-agent nivolumab, althoughwith a lower frequency (5% according
to Hodi et al., 2013b), and less commonly with the combination of
nivolumab and ipilimumab (Sznol et al., 2014). Certainly, in the case
of the two randomized Phase II trials of ipilimumab and chemotherapy
in NSCL and small cell lung cancer, it was the adoption of immune-
related PFS criteria that helped in the selection of the sequential
regimens that were brought into Phase III.
The immune-related response criteria were initially developed as a
tool to help the oncologist and the patient to better decide if continua-
tion of treatment could be warranted even in the presence of a tumor
progression. This goes against the criteria by which oncologists have
been historically trained to operate and can provide a sense of the difﬁ-
culties that innovation brings about. The immune-related response
criteria still need prospective validation before becoming accepted as
regulatory endpoints. However, regulatory health authorities have al-
ready accepted the concept of “treating beyond progression” in selected
cases of anticancer drug development (FDA/Center for Biologics
Evaluation & Research [CBER], 2011; European Medicines Agency
[EMA], 2012).
4.2.2. Long-term effects and their prediction
The kinetics of survival also appears to differ between immunologic
and traditional therapies (Hoos et al., 2010b). The long-adopted tenet
bywhich events in a time-to-event analysis occur by constant proportion-
al hazard is being challenged by the shape of survival curves presented in
this review in Figs. 2 and 3. One of the practical consequences of this
situation is that a classical event-driven study design might require
very long times to reach its maturity. Thus, the question of identifying
proper predictors and/or surrogates for long-term survival has become
very important.
Two different exploratory approaches have been proposed by BMS.
First, an analysis has been conducted of the association of tumor shrink-
age and OS (Feng et al., 2014). Although this methodology had been
previously utilized for standard treatments in lung and colorectal cancer
(Wang et al., 2009; Suzuki et al., 2012; Bruno et al., 2014), it had not
been tested with immunological therapies. Databases of single-agent
ipilimumab and nivolumab in various tumor types were utilized, and
tumor assessments at week 8 or 12 were analyzed, together with the
relative pharmacokinetics results, in order to develop a tumor growth
dynamics model to be used to predict survival outcomes.
In the case of ipilimumab in melanoma, the ECOG performance sta-
tus, baseline LDH, drug clearance and percent tumor shrinkage at week
8 predicted for survival outcomes. Of note, drug exposure did not. In the
case of nivolumab in melanoma and NSCL cancer, again the percent
tumor shrinkage at 8weekspredicted for survival. This type ofmodeling
will need a validation from a prospective experiment, but it could help
reﬁning the possibility of an early prediction of the ultimate patient
beneﬁt.
A second approach has been taken by modeling an analysis of OS in
metastatic melanoma patients which takes into consideration the ‘stabili-
zation’ of the survival curve after two to three years of follow-up, as seen
in Figs. 2 and 3. A total of 10,000 simulations were carried out, showing
that, based on a standard approach with a proportional (exponential)
hazard model, a much longer trial would be needed and/or the study
power will be reduced (Chen, 2013a). A proposed ‘milestone’ analysis,
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result in savings in the size of the trial as well as in the time of study anal-
ysis, preserving statistical power even in the presence of delayed effects.
Moreover, this type of analysis could maintain the integrity of the study
if there were a desire to maintain the standard log-rank analysis to
characterize ﬁnal survival results. And, obviously, this analysis could be
performed only in the presence of a robust supporting prior evidence of
outcome stabilization (Chen, 2013b).
4.2.3. Dosing regimens
Whereas traditional cytotoxic therapy generally presents dose-
dependent effects resulting in the deﬁnition of dose-limiting toxicities
and of a maximum tolerated dose, recently introduced novel targeted
therapies do not always follow this pattern. The same consideration
applies to immune checkpoint-directed therapy, compounded by the
fact that the therapeutic target is not located at the tumor level.
In the case of ipilimumab, Phase I trials were unable to attain a max-
imum tolerated dose up to a dose of 20mg/kg (Weber et al., 2008). Based
on an in vitro cell-based competition assay measuring the blockade of
the CTLA-4 binding to the B7-1 ligand, it was determined that a maxi-
mum effect was sustained at concentrations of 20 μg/ml of ipilimumab.
These concentrations could not be achieved in patients given a dose of
0.3 mg/kg but were achieved in about 30% of patients given 3 mg/kg
and in 95% of patients given 10mg/kg. Of note, steady-state was reached
in most patients after three induction doses of ipilimumab (Dai et al.,
2008). These analyses reported also an association between exposure
and the occurrence of immune-related AEs. These data supported the
conduct of many ipilimumab studies at 10 mg/kg, which began before
the results of the ﬁrst Phase III trial of ipilimumab at 3 mg/kg became
available.
A randomized trial (Wolchok et al., 2010a) suggested the existence
of a potential clinically relevant dose effect over the range of 0.3, 3 and
10 mg/kg, reaching statistical signiﬁcance for response rates. However,
as patients who experienced tumor progression in the two lower-dose
arms were re-challenged with ipilimumab at 10 mg/kg, long-term sur-
vival effects are not informative. Of note, a dose–effect appeared to
exist also for the safety aspect of the equation. The question of optimal
dosing of ipilimumab is being addressed by two large Phase III trials in
melanoma, one being conducted inmetastatic and one being conducted
in the adjuvant setting. At the time of this writing, both trials have com-
pleted their accrual (ClinicalTrials.gov; NCT01515189; NCT01274338).
Although initial trials of ipilimumab adopted only the four induction
doses regimen, subsequent trials have proposed the administration of
maintenance therapy. In each of the Phase III trials in ﬁrst-linemetasta-
tic melanoma (Robert et al., 2011), in adjuvant melanoma (Eggermont
et al., 2014) and in prostate cancer (Kwon et al., 2014) a maintenance
regimen of 10 mg/kg given every 12 weeks was adopted. Patients who
received maintenance in the ipilimumab arms were 17%, 42% and 24%,
respectively. Whereas it is clear that less heavily pretreated patients
(in the adjuvant trial) had a higher rate of compliance, the role of main-
tenance therapy and its tolerability still needs to be fully elucidated.
In the case of nivolumab, a clear dose–effect was not established
with a possible exception of efﬁcacy at the lowest dosage tested
in NSCL cancer. Whereas the pharmacokinetics of the antibody were
linear, PD-1 receptor occupancy was assessed by antibody binding of
circulating CD3+T-cells and it ranged from 64 to 72% at all doses tested
in the Phase I trials (Brahmer et al., 2010; Topalian et al., 2012). Serum
half-life of nivolumab was 12 days at doses of 3 mg/kg and below, and
20 days at doses of 10 mg/kg. On the basis of these data, and also by
virtue of the favorable safety proﬁle observed, the regimen selected
for further development of nivolumab was 3 mg/kg every two weeks
or equivalent regimens administered every three weeks.
For BMS-936559 (anti-PD-L1), data were similar, with lack of a
dose–effect, linear pharmacokinetics, half-life of 15 days andmedian re-
ceptor occupancy exceeding 65% in all dose cohorts treated (Brahmer
et al., 2012). The issue of lack of responsiveness to immunotherapy, asopposed to the classical concept of tumor resistance, can be addressed
by reinduction treatment.
In the case of ipilimumab, reinduction was studied in metastatic
melanoma patients who had disease progression after completing
their induction, with or without maintenance. With ipilimumab, in a
series of six Phase II trials whose patients received reinduction at
10 mg/kg, a total of seven CR and 21 PRs (23%) with 31 additional SD
were observed in 122 reinduced patients (Neyns et al., 2013). In the
Phase III trial for previously treated patients, patients were reinducted
with ipilimumab 3 mg/kg (and gp100 if they had been randomized to
the combination arm). A total of one CR and six PRs (18%) with 14 SD
were observed in 38 patients. Neither of the patients reinduced with
gp100 alone responded (Robert et al., 2010). Finally, reinduction was
allowed also for patients who were accrued to the EAP. In the EAP
that adopted 3 mg/kg, reinduction was administered at the same
dosage. Whereas objective response data were not collected, median
survival in 108 reinduced patients was 21.1 months, with one- and
two-year survivals of 81% and 43%, respectively (K.A. Margolin et al.,
2013). Of note, the incidence of grade III–IV immune-related AEs during
reinduction was 14% at 10 mg/kg and 5% in both series at 3 mg/kg.
The published experience of reinduction therapy with nivolumab is,
so far, limited to a single, previously-treatedmelanomapatientwhohad
been accrued to the ﬁrst Phase I trial (Brahmer et al., 2010) and obtained,
after receiving multiple doses of 10 mg/kg, a PR, discontinued treatment
after several months of therapy and remained in response for an addi-
tional 22 months without therapy. Upon relapsing, the patient was
reinduced with nivolumab and obtained a PR lasting for 16+ months
(Lipson et al., 2013).
4.3. Biomarkers
4.3.1. Prognostic factors (ipilimumab)
In discussing the key question of the role of biomarkers in cancer
treatment, it is important to take into consideration both clinical and
mechanistic (biological) factors. For instance, in the case of ipilimumab,
the vastmajority of the predeﬁned clinical subsets of potential prognos-
tic value in all of the Phase III trials completed pointed to a positive effect
of treatment. These included age, gender, disease stage, ulceration of
primary LDH, liver function tests, prior treatment, Gleason score, pain
and geography (Hodi et al., 2010; Robert et al., 2011; Eggermont et al.,
2014; Kwon et al., 2014). The few exceptions were women with
age ≥ 50 years in the Robert trial, unknown status of tumor ulceration
in the Eggermont trial, and presence of visceral metastases in the
Kwon trial. Given the usually small number of patients in subsets and
the fact that conﬁdence intervals are quite wide, these results must be
viewed in the proper context. It would appear that these clinical factors
might have more of a prognostic than a predictive role as an effect was
observed also for the less favorable subsets.
4.3.2. Predictive factors (ipilimumab)
Understanding the mechanism of pharmacologic immune modula-
tion becomes quite complex, as both the biomarkers that are inherent
to the tumor cell and those that involve the T-cell activation are
relevant. Moreover, the variations that might occur over time in the
tumor microenvironment also need to be considered, as the so-called
‘plasticity’ of the immune system response might become apparent
only after the beginning of treatment (Ascierto et al., 2013).
The next step in the search of potential predictive biomarkers might
involve the genomic characterization associated with outcome. Initial
reports have indicated that the CT60 G/A genotype may be associated
with both better response and OS in melanoma (Queirolo et al., 2011).
However, the results of genetic polymorphism have not been conﬁrmed
(Hamid et al., 2011). Somatic diversiﬁcation of the T-cell repertoiremay
also provide a characteristic which may deﬁne the antitumor immune
response. A decline in the number of diversiﬁed T-cell clonotypes
Fig. 5. The promise and the present of metastatic melanoma therapy with immune. checkpoint inhibitors.
148 D. Berman et al. / Pharmacology & Therapeutics 148 (2015) 132–153might be associated with shorter OS in both prostate cancer and mela-
noma (Fong et al., 2014).
The existence of immunologic predictive biomarkers has been also
interrogated with serial tumor biopsies conducted in a Phase II trial of
ipilimumab in melanoma (Hamid et al., 2011). Whereas there was no
correlation between the baseline presence of TIL and clinical beneﬁt
(deﬁned as CR, PR or SD), an increase of TILs after treatment was
associated with clinical beneﬁt. FOXP3 and IDO expression at baseline
immunostaining of leukocytes, however, did correlate with positive
clinical beneﬁt for ipilimumab treatment.
4.3.3. Predictive factors (PD-1/PD-L1 pathway)
The assessment of potential pharmacodynamic and predictive
biomarkers at the tumor and microenvironmental level is even more
important in the case of nivolumab, due to the expression of the
PD-L1 ligand on tumors and TILs, and of PD-L2 on macrophages and
dendritic cells. Differences in the type of assays utilized to assess ligand
expression must be considered when reviewing the current informa-
tion. In the Phase I trial by Topalian (Topalian et al., 2012) a murine
antitumor PD-L1 monoclonal antibody, 5H1, was utilized on formalin-
ﬁxed, parafﬁn-embedded new or archived specimens. Positivity was
deﬁned by a 5% expression threshold. With this technique, 9/25
responses were seen in PD-L1 positive and 0/17 in PD-L1 negative
patients. A different approach, which utilized an automated assay and a
differentmonoclonal antibody, 28-8,was also tested, identifying 7/16 re-
sponses in PD-L1 positive and 3/18 responses in PD-L1 negative patients.
In this series, which considered ≥ 5% cell membrane staining as a posi-
tive result, PD-L1 positivity appeared also to correlate with longer PFS
and OS (Grosso et al., 2013). Other studies with other monoclonals
affecting the PD-1/PD-L1 pathway have adopted other assays, cut-off
and evaluation criteria, including PD-L1 expression on both tumor cells
and TILs (Powderly et al., 2013; Daud et al., 2014).
4.3.4. Predictive factors (sequence and combination)
Unlike biomarkers that reﬂect mutations in tumor DNA, those of
checkpoint inhibitors at the tumor and microenvironment level can be
more dynamic, depending upon changes in time and in prior exposure
to agentswhich can enhance it. Indeed PD-L1 expression can be induced
by cytokine exposure, CTLA-4 expression on the TIL can be increased by
nivolumab treatment, and PD-1 expression is induced in T cells after
CTLA-4 blockade (Curran et al., 2010; M. Selby et al., 2013). In patients
previously exposed to ipilimumab, the sequential treatment with
nivolumab produced 4/8 responses in PD-L1 positive and 1/13 re-
sponses in PD-L1 negative melanoma patients (28.8 antibody staining)
(Callahan et al., 2013). Thus, the observation of tumor responses even in
the PD-L1 negative population was conﬁrmed. More importantly, the
concomitant administration of ipilimumab and nivolumab produced6/13 responses in PD-L1 positive and 9/22 responses in PD-L1 negative
patients: the latter observation suggests that the combined regimen
efﬁcacy might not depend solely upon ligand expression (Callahan
et al., 2013).
In this trial, the combination regimen produced responses in
patients, irrespective of their baseline absolute lymphocyte count, and
increases of HLA-DR+ CD4+ and CD8+ T-cells and of Ki67+ CD4+
and CD8+ T cells were also produced. However, low levels of myeloid-
derived suppressor cells correlated with better response.
Notwithstanding the differences in assays, it appears that ligand
overexpression correlates with better responses when blocking the
PD-1/PD-L1 pathway. However, given the plasticity of the immune sys-
tem and the observation of antitumor effects even in the PD-L1 negative
population, it will be important to correlate ligand expression with
the hoped-for long-term effects of treatment. Thus, it is expected that
validation of the ligand expression as a predictive biomarker will be
possible only upon the availability of long-term results from Phase III
trials. Fortunately the vast majority of such trials have been designed
prospectively with this need in mind.
5. Conclusions
The progress in understanding the immune system in general and
the immune checkpoint modulation in particular is allowing a new
chapter to be written in the history of drug development.
It is clear that a new modality of cancer treatment is being intro-
duced which would integrate with or possibly substitute traditional
forms of therapy.
The availability of multiple agents with different mechanisms of
immunologic response activation poses the challenge but also offers
the opportunity for further innovation.
What was presented only a few years ago as the promise of a novel
approach is now delivering results that, if conﬁrmed, might exceed
those predictions (Fig. 5).
The continuous connectivity betweendrug developers andacademic
investigators, bench scientists and clinical oncologists is the formula
that can accelerate this process.
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